<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VET</journal-id>
<journal-id journal-id-type="hwp">spvet</journal-id>
<journal-id journal-id-type="nlm-ta">Vet Pathol</journal-id>
<journal-title>Veterinary Pathology</journal-title>
<issn pub-type="ppub">0300-9858</issn>
<issn pub-type="epub">1544-4221</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300985811398252</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300985811398252</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Pathology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Primary Neoplasms of Bones in Mice</article-title>
<subtitle>Retrospective Study and Review of Literature</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kavirayani</surname>
<given-names>A. M.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300985811398252">1</xref><xref ref-type="corresp" rid="corresp1-0300985811398252"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sundberg</surname>
<given-names>J. P.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300985811398252">1</xref></contrib>
<contrib contrib-type="author">
<name>
<surname>Foreman</surname>
<given-names>O.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300985811398252">1</xref></contrib>
</contrib-group>
<aff id="aff1-0300985811398252"><label>1</label>The Jackson Laboratory, Bar Harbor, Maine</aff>
<author-notes>
<corresp id="corresp1-0300985811398252">Anoop Murthy Kavirayani, Mail Box 113, Bar Harbor, ME 04609 Email: <email>kavirayam@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>49</volume>
<issue>1</issue>
<fpage>182</fpage>
<lpage>205</lpage>
<permissions>
<copyright-statement>© American College of Veterinary Pathologists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">American College of Veterinary Pathologists</copyright-holder>
</permissions>
<abstract>
<p>To compare and summarize the mechanisms, frequencies of occurrence, and classification schemes of spontaneous, experimental, and genetically engineered mouse skeletal neoplasms, the literature was reviewed, and archived case material at The Jackson Laboratory was examined. The frequency of occurrence of spontaneous bone neoplasms was less than 1% for most strains, with the exceptions of osteomas in CF-1 (5.5% and 10% in two studies) and OF-1 outbred strains (35%), and osteosarcomas in NOD/ShiLtJ (11.5%) and NOD-derived (7.1%) mice. The frequency was 100% for osteochondromas induced by conditional inactivation of exostoses (multiple) 1 (<italic>Ext1</italic>) in chondrocytes, osteosarcomas induced by tibial intramedullary inoculation of Moloney murine sarcoma virus, and osteosarcomas induced by conditional inactivation of <italic>Trp53</italic>—with or without inactivation of <italic>Rb1</italic>—in osteoblast precursors. Spontaneous osteogenic neoplasms were more frequent than spontaneous cartilaginous and vascular types. Malignant neoplasms were more frequent than benign ones. The age of occurrence for spontaneous neoplasms ranged from 37 to 720 days (<italic>M</italic> = 316.35) for benign neoplasms and 35 to 990 (<italic>M</italic> = 299.28) days for malignant. In genetically engineered mice, the average age of occurrence ranged from 28 to 70 days for benign and from 35 to 690 days for malignant. Histologically, nonosteogenic neoplasms were similar across strains and mutant stocks; osteogenic neoplasms exhibited greater diversity. This comparison and summarization of mouse bone neoplasms provides valuable information for the selection of strains to create, compare, and validate models of bone neoplasms.</p>
</abstract>
<kwd-group>
<kwd>bone tumors</kwd>
<kwd>chondroma</kwd>
<kwd>chondrosarcoma</kwd>
<kwd>hemangioma</kwd>
<kwd>hemangiosarcoma</kwd>
<kwd>laboratory mice</kwd>
<kwd>mouse models</kwd>
<kwd>ossifying fibroma</kwd>
<kwd>osteoma</kwd>
<kwd>osteosarcoma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Neoplastic lesions of bone are less common in humans, domestic animals, and laboratory mice, compared to neoplasms of other tissues.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>-<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr68-0300985811398252">68</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Malignant neoplasms of bone are generally more common than the benign, and osteosarcoma is the most common skeletal neoplastic lesion in all species, including laboratory mice.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref>,<xref ref-type="bibr" rid="bibr56-0300985811398252">56</xref>,<xref ref-type="bibr" rid="bibr68-0300985811398252">68</xref>,<xref ref-type="bibr" rid="bibr69-0300985811398252">69</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Benign tumors of bones that have been reported to occur spontaneously in mice include chondroma, hemangioma, ossifying fibroma, osteoblastoma, and osteoma.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr59-0300985811398252">59</xref>,<xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref>,<xref ref-type="bibr" rid="bibr78-0300985811398252">78</xref>,<xref ref-type="bibr" rid="bibr79-0300985811398252">79</xref>,<xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref></sup> Spontaneous malignant neoplasms of bone reported in mice include chondrosarcoma, hemangiosarcoma, and osteosarcoma.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr60-0300985811398252">60</xref>,<xref ref-type="bibr" rid="bibr78-0300985811398252">78</xref>,<xref ref-type="bibr" rid="bibr79-0300985811398252">79</xref>,<xref ref-type="bibr" rid="bibr94-0300985811398252">94</xref>,<xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref></sup></p>
<p>This article addresses the similarities and differences in classification schemes for neoplasms of bone in humans, domestic animals, and laboratory mice. It also presents a comparison and summary of neoplasms of bone—spontaneous, genetically engineered, radiation induced, and chemically induced—in various strains of laboratory mice (as noted in the literature), as well as a retrospective evaluation of the frequency of bone neoplasms in various mouse strains submitted for diagnostic necropsy at The Jackson Laboratory (Bar Harbor, Maine).</p>
<sec id="section1-0300985811398252">
<title>Materials and Methods</title>
<p>We reviewed reports of spontaneous, experimentally induced, or genetically engineered primary skeletal neoplasms in inbred, hybrid, genetically engineered, and outbred strains and stocks of mice and summarized the mechanisms, frequencies of occurrence, and other features of these neoplasms. Additional details on the strains of mice, genetic manipulations, and experimental procedures are available in the cited references.</p>
<p>For retrospective evaluation of the frequency of bone neoplasms at The Jackson Laboratory, we reviewed archived necropsy records and glass slides for diagnoses of bone neoplasms in various strains submitted to the diagnostic service for necropsy between January 1987 and January 2010. Criteria for submission were clinical assessment of a “sick mouse” or the presence of a grossly visible tumor. Gross necropsy examination was performed on all mice, and collected tissues were fixed in Tellyesniczky/Fekete fixative (70% ethanol, 100 ml; 37–40% formalin, 5 ml; glacial acetic acid, 5 ml).<sup><xref ref-type="bibr" rid="bibr88-0300985811398252">88</xref></sup> Appropriate tissues were decalcified with 10% formic acid (Formical-2000, Decal Chemical Corporation, Tallman, New York) or 3% hydrochloric acid (Cal-Ex, Fisher Scientific, Fairlawn, New Jersey) for 24 hours. Tissues were paraffin embedded and stained with hematoxylin and eosin. Diagnoses were reviewed and neoplasms classified according to criteria described in the <italic>International Classification of Rodent Tumors: The Mouse.</italic>
<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup> Diagnostic designations were also compared with listings on the mouse pathology ontology system (<ext-link ext-link-type="uri" xlink:href="http://eulep.pdn.cam.ac.uk/Pathology_Ontology/index.php">http://eulep.pdn.cam.ac.uk/Pathology_Ontology/index.php</ext-link>, September 2010). Archived and current designations were in agreement for most diagnostic entities. The designation of <italic>osteochondrosarcoma</italic>, as used in the archives, was not reiterated in the retrospective evaluation. Cartilage or chondroid matrix–rich osteosarcomas are currently classified as osteosarcomas of the chondroblastic subtype.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref></sup> Diagnoses of many differentiated primary skeletal neoplasms predominantly rely on radiographic and histologic features rather than on immunohistochemical studies.<sup><xref ref-type="bibr" rid="bibr28-0300985811398252">28</xref></sup> In this study, most tumors were well differentiated; so, diagnoses were based on histomorphologic features, and immunohistochemistry was not required.</p>
<p>For any strain that had fewer than 100 total necropsy submissions, the frequency of occurrence was not considered representative. Details of the age of occurrence and frequency of benign and malignant neoplasms sorted by sex are available in Supplementary <xref ref-type="table" rid="table1-0300985811398252">Tables 1</xref> and <xref ref-type="table" rid="table2-0300985811398252">2</xref> (available at <ext-link ext-link-type="uri" xlink:href="http://vet.sagepub.com/supplemental">http://vet.sagepub.com/supplemental</ext-link>).</p>
<table-wrap id="table1-0300985811398252" position="float">
<label>Table 1.</label>
<caption>
<p>Classification Schemes for Bone Tumors<sup><xref ref-type="table-fn" rid="table-fn1-0300985811398252">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0300985811398252" xlink:href="10.1177_0300985811398252-table1.tif"/>
<graphic alternate-form-of="table1-0300985811398252" xlink:href="10.1177_0300985811398252-table1a.tif"/>
<graphic alternate-form-of="table1-0300985811398252" xlink:href="10.1177_0300985811398252-table1b.tif"/>
<graphic alternate-form-of="table1-0300985811398252" xlink:href="10.1177_0300985811398252-table1c.tif"/>
<graphic alternate-form-of="table1-0300985811398252" xlink:href="10.1177_0300985811398252-table1d.tif"/>
<table>
<thead>
<tr>
<th align="left" colspan="2">World Health Organization</th>
<th align="left">
</th>
<th align="left">
</th>
<th align="left">
</th>
<th align="left">
</th>
</tr>
<tr>
<th align="left">Human Beings<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref></sup></th>
<th align="left">Domestic Animals<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup></th>
<th align="left">International Classification of Rodent Tumors<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup></th>
<th align="left">Corresponding Spontaneous Tumors in Laboratory Mice<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr68-0300985811398252">68</xref>,<xref ref-type="bibr" rid="bibr69-0300985811398252">69</xref></sup></th>
<th align="left">Corresponding Genetically Engineered Mouse Models</th>
<th align="left">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6">
<italic>CARTILAGINOUS TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Osteochondroma</td>
<td align="left">Osteochondroma</td>
<td align="left">NCDE</td>
<td align="left">Osteochondroma</td>
<td align="left">Conditional inactivation of <italic>Ext1<sup>e2ne</sup>°<sup>fl</sup></italic> or <italic>Ext1<sup>e2fl</sup></italic> in chondrocytes;<sup><xref ref-type="bibr" rid="bibr46-0300985811398252">46</xref></sup> targeted mutation of <italic>Ext2</italic>
<sup><xref ref-type="bibr" rid="bibr91-0300985811398252">91</xref></sup></td>
<td align="left">Models for multiple hereditary exostoses or multiple osteochondromas<sup><xref ref-type="bibr" rid="bibr46-0300985811398252">46</xref>,<xref ref-type="bibr" rid="bibr91-0300985811398252">91</xref></sup></td>
</tr>
<tr>
<td align="left">NA</td>
<td align="left">Osteochondromatosis (feline)</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Chondroma</td>
<td align="left">Chondroma</td>
<td align="left">Chondroma</td>
<td align="left">Chondroma</td>
<td align="left">See below</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Enchondroma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">Transgenic overexpression of <italic>Gli2</italic> in chondrocytes;<sup><xref ref-type="bibr" rid="bibr35-0300985811398252">35</xref></sup> transgenic expression of mutant human <italic>PTH/PTHrP</italic> type I receptor <italic>(R150CPTHR1)</italic> in growth plates<sup><xref ref-type="bibr" rid="bibr37-0300985811398252">37</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Periosteal chondroma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Multiple chondromatosis</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Chondroblastoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Chondromyxoid fibroma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Chondromyxoid fibroma</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Chondrosarcoma</td>
<td align="left">Chondrosarcoma</td>
<td align="left">Chondrosarcoma</td>
<td align="left">Chondrosarcoma</td>
<td align="left">Transgenic overexpression of <italic>Gli2</italic> in combination with inactivation of <italic>Trp53</italic> (<italic>Trp53+/-</italic>) in chondrocytes;<sup><xref ref-type="bibr" rid="bibr35-0300985811398252">35</xref></sup> targeted mutation of <italic>Nfatc2</italic> (<italic>Nfatp</italic>)<sup><xref ref-type="bibr" rid="bibr84-0300985811398252">84</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Central, primary and secondary</td>
<td align="left">Central chondrosarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCLS</td>
<td align="left">NCLS</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Peripheral</td>
<td align="left">Periosteal chondrosarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCLS</td>
<td align="left">NCLS</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Dedifferentiated</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCLS</td>
<td align="left">NCLS</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Mesenchymal</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCLS</td>
<td align="left">NCLS</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Clear cell</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCLS</td>
<td align="left">NCLS</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>OSTEOGENIC TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Osteoid osteoma</td>
<td align="left">Osteoma</td>
<td align="left">Osteoma</td>
<td align="left">Osteoma</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Osteoblastoma</td>
<td align="left">NCDE</td>
<td align="left">Osteoblastoma/ osteofibroma</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Listed synonymously with osteoblastoma</td>
<td align="left">Osteofibroma</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Osteosarcoma</td>
<td align="left">Osteosarcoma</td>
<td align="left">Osteosarcoma</td>
<td align="left">Osteosarcoma</td>
<td align="left">Transgenic expression of <italic>H2-cfosLTR</italic>
<sup><xref ref-type="bibr" rid="bibr16-0300985811398252">16</xref>,<xref ref-type="bibr" rid="bibr31-0300985811398252">31</xref>,<xref ref-type="bibr" rid="bibr87-0300985811398252">87</xref></sup> and Simian virus 40 T antigen;<sup><xref ref-type="bibr" rid="bibr5-0300985811398252">5</xref>,<xref ref-type="bibr" rid="bibr40-0300985811398252">40</xref>,<xref ref-type="bibr" rid="bibr51-0300985811398252">51</xref>,<xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref>,<xref ref-type="bibr" rid="bibr106-0300985811398252">106</xref></sup> conditional inactivation of <italic>Trp53</italic> and <italic>Rb1</italic>;<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref>,<xref ref-type="bibr" rid="bibr101-0300985811398252">101</xref></sup> targeted mutation of <italic>Trp53</italic>,<sup><xref ref-type="bibr" rid="bibr18-0300985811398252">18</xref>,<xref ref-type="bibr" rid="bibr19-0300985811398252">19</xref>,<xref ref-type="bibr" rid="bibr33-0300985811398252">33</xref>,<xref ref-type="bibr" rid="bibr44-0300985811398252">44</xref></sup><italic>Cdkn2a</italic>,<sup><xref ref-type="bibr" rid="bibr20-0300985811398252">20</xref></sup><italic>Bax</italic> and <italic>Cdkn2a</italic>,<sup><xref ref-type="bibr" rid="bibr20-0300985811398252">20</xref></sup><italic>Nf2</italic>,<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup> and <italic>Nf2</italic> and <italic>Trp53</italic>
<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup></td>
<td align="left">Various subtypes of osteosarcoma are infrequently described in genetically engineered mouse models of osteosarcoma</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Poorly differentiated</td>
<td align="left">NCDE</td>
<td align="left">Poorly differentiated</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Conventional</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Eburnating</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Chondroblastic</td>
<td align="left">Chondroblastic</td>
<td align="left">Chrondroblastic</td>
<td align="left">Chondroblastic</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Fibroblastic</td>
<td align="left">Fibroblastic</td>
<td align="left">Fibroblastic</td>
<td align="left">Fibroblastic</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Osteoblastic</td>
<td align="left">Osteoblastic</td>
<td align="left">Osteoblastic</td>
<td align="left">Osteoblastic</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Osteoclastic</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Vascular</td>
<td align="left">Vascular</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Anaplastic</td>
<td align="left">Anaplastic</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Mixed</td>
<td align="left">Mixed</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Sclerosing</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Telangiectatic</td>
<td align="left">Telangiectatic</td>
<td align="left">NCDE</td>
<td align="left">Telangiectatic</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Giant cell type</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Small cell</td>
<td align="left">NCDL</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Low-grade central</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Secondary</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Parosteal</td>
<td align="left">Parosteal</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Periosteal</td>
<td align="left">Periosteal</td>
<td align="left">NCDE</td>
<td align="left">Periosteal</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">High-grade surface</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">
</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Multilobular tumor of bone</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>FIBROGENIC TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Desmoplastic fibroma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Fibrosarcoma</td>
<td align="left">Fibrosarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Periosteal fibrosarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Maxillary fibrosarcoma (dogs)</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>FIBROHISTIOCYTIC TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Benign fibrous histiocytoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Malignant fibrous histiocytoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>EWING SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR</italic>
</td>
</tr>
<tr>
<td align="left">Ewing sarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">Transgenic expression of <italic>EWS-FLI1</italic> (poorly differentiated sarcoma)<sup><xref ref-type="bibr" rid="bibr53-0300985811398252">53</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>HEMATOPOIETIC TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Plasma cell myeloma</td>
<td align="left">Myeloma</td>
<td align="left">NCDE</td>
<td align="left">Myeloma<sup><xref ref-type="bibr" rid="bibr82-0300985811398252">82</xref>,<xref ref-type="bibr" rid="bibr83-0300985811398252">83</xref></sup></td>
<td align="left">Transgenic expression of <italic>Xbp-1</italic> - Tg(<italic>Eµ-Xbp-1</italic>);<sup><xref ref-type="bibr" rid="bibr8-0300985811398252">8</xref></sup> transgenic expression of mutant <italic>Myc</italic> (<italic>Vk*Myc</italic>)<sup><xref ref-type="bibr" rid="bibr13-0300985811398252">13</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Malignant lymphoma, NOS</td>
<td align="left">Malignant lymphoma</td>
<td align="left">NCDE</td>
<td align="left">Malignant lymphoma</td>
<td align="left">Transgenic overexpression of <italic>Myc</italic>;<sup><xref ref-type="bibr" rid="bibr47-0300985811398252">47</xref></sup> transgenic expression of mutant <italic>Myc</italic> (<italic>Vk*Myc</italic>)<sup><xref ref-type="bibr" rid="bibr13-0300985811398252">13</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Mastocytoma</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>GIANT CELL TUMOR</italic>
</td>
</tr>
<tr>
<td align="left">Giant cell tumour</td>
<td align="left">Giant cell tumor of bone</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Malignancy in giant cell tumour</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>NOTOCHORDAL TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Chordoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Chordoma</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>VASCULAR TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Haemangioma</td>
<td align="left">Hemangioma</td>
<td align="left">NCDE</td>
<td align="left">Hemangioma<break/>Hemangioendothelioma</td>
<td align="left">NCLM</td>
<td align="left">Specific models of intraosseous hemangioma are uncommon</td>
</tr>
<tr>
<td align="left">Angiosarcoma</td>
<td align="left">Hemangiosarcoma</td>
<td align="left">NCDE</td>
<td align="left">Hemangiosarcoma<break/>Angiosarcoma</td>
<td align="left">NCLM</td>
<td align="left">Specific models of intraosseous hemangiosarcoma are uncommon</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>SMOOTH MUSCLE TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Leiomyoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Leiomyosarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>LIPOGENIC TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Lipoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Liposarcoma</td>
<td align="left">Liposarcoma</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>NEURAL TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Neurilemmoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>MISCELLANEOUS TUMORS</italic>
</td>
</tr>
<tr>
<td align="left">Adamantinoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">Adamantinoma is listed synonymously with ameloblastoma under tumors of teeth in the mouse classification system<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup></td>
</tr>
<tr>
<td align="left">Metastatic malignancy</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Malignant mesenchymoma</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Others</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>MISCELLANEOUS LESIONS</italic>
</td>
</tr>
<tr>
<td align="left">Aneurysmal bone cyst</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Aneurysmal bone cyst</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Simple cyst</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">Bone cyst</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Solitary bone cyst</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Juxtacortical bone cyst</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Epidermoid cyst of the phalanx</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Myositis ossificans</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">Myositis ossificans is considered under nonneoplastic diseases of bones<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref></sup> and tumors of soft tissue<sup><xref ref-type="bibr" rid="bibr24-0300985811398252">24</xref></sup> in human beings.</td>
</tr>
<tr>
<td align="left">Fibrous dysplasia</td>
<td align="left">Fibrous dysplasia</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Myxoma of the jaw</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Osteofibrous dysplasia</td>
<td align="left">Ossifying fibroma</td>
<td align="left">Ossifying fibroma /Cementifying fibroma</td>
<td align="left">Ossifying fibroma</td>
<td align="left">NCLM</td>
<td align="left">Osteofibrous dysplasia is currently used for conditions previously described as ossifying fibroma<sup><xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup></td>
</tr>
<tr>
<td align="left">Langerhans cell histiocytosis</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">Multisystem histiocytosis<sup><xref ref-type="bibr" rid="bibr90-0300985811398252">90</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Erdheim-Chester disease</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Chest wall hamartoma</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
<tr>
<td align="left" colspan="6">
<italic>JOINT LESIONS</italic>
</td>
</tr>
<tr>
<td align="left">Synovial chondromatosis</td>
<td align="left">NCDE</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">Disruption of hedgehog signaling in <italic>Gli3</italic> mutants;<sup><xref ref-type="bibr" rid="bibr38-0300985811398252">38</xref></sup> transgenic expression of Simian virus 40 tumor antigen<sup><xref ref-type="bibr" rid="bibr98-0300985811398252">98</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Synovial sarcoma</td>
<td align="left">Synovial sarcoma</td>
<td align="left">Synovial sarcoma</td>
<td align="left">Conditional expression of human <italic>SYT-SSX</italic> in <italic>Myf5</italic> expressing myoblasts<sup><xref ref-type="bibr" rid="bibr32-0300985811398252">32</xref></sup></td>
<td align="left">
</td>
</tr>
<tr>
<td align="left">NCDE</td>
<td align="left">Villonodular synovitis</td>
<td align="left">NCDE</td>
<td align="left">NCDL</td>
<td align="left">NCLM</td>
<td align="left">
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300985811398252">
<p>
<sup>a</sup> NA, not applicable to the species; NCDE, no corresponding designation or entry in this classification scheme; NCDL, not commonly diagnosed or listed as a primary tumor of bone or joint; NCLM, no commonly listed genetically engineered mouse model with primary involvement of bone or joint; NCLS, not commonly listed as a subtype.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0300985811398252" position="float">
<label>Table 2.</label>
<caption>
<p>Benign Bone Tumors in Various Strains of Mice as Reported in the Literature</p>
</caption>
<graphic alternate-form-of="table2-0300985811398252" xlink:href="10.1177_0300985811398252-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
</th>
<th>
</th>
<th align="center" colspan="3">Tumor Frequency, %</th>
</tr>
<tr>
<th>Mouse Strain</th>
<th>Mechanism</th>
<th>Age at Necropsy<sup><xref ref-type="table-fn" rid="table-fn2-0300985811398252">a</xref></sup></th>
<th>Both Sexes</th>
<th>Males</th>
<th>Females</th>
</tr>
<tr>
<th colspan="6">
<italic>CARTILAGINOUS TUMORS</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chondroma</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> C57BL/10J<sup><xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref>,<xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup></td>
<td>Spontaneous</td>
<td>18 to 24 months</td>
<td>0.05 (2/3,968)</td>
<td>0</td>
<td>0.1 (2/1,984)</td>
</tr>
<tr>
<td> Strain not specified, Tg(<italic>Gli2</italic>;<italic>Col2a1</italic>)<sup><xref ref-type="bibr" rid="bibr35-0300985811398252">35</xref></sup></td>
<td>Transgenic overexpression of <italic>Gli2</italic> in chondrocytes</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Strain not specified, Tg(<italic>Gli2</italic>;<italic>Col2a1</italic>;<italic>PTHR1</italic>)<sup><xref ref-type="bibr" rid="bibr37-0300985811398252">37</xref></sup></td>
<td>Transgenic expression of mutant human PTH/PTHrP type I receptor (<italic>R150CPTHR1</italic>) in growth plates</td>
<td>From 8 weeks</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">Chondromyxoid fibroma</td>
</tr>
<tr>
<td> C57BL/10J<sup><xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref>,<xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup></td>
<td>Spontaneous</td>
<td>24 months</td>
<td>0.02 (1/3,968)</td>
<td>0.04 (1/1,984)</td>
<td>0</td>
</tr>
<tr>
<td colspan="6">Osteochondroma</td>
</tr>
<tr>
<td> B6C3F1<sup><xref ref-type="bibr" rid="bibr104-0300985811398252">104</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.02 (1/5,065)</td>
<td>0.03 (1 of 2,543)</td>
<td>0</td>
</tr>
<tr>
<td> B6;129-<italic>Ext1<sup>tm1Kjns</sup></italic>
<sup><xref ref-type="bibr" rid="bibr46-0300985811398252">46</xref></sup></td>
<td>Conditional inactivation of <italic>Ext1<sup>e2ne</sup>°<sup>fl</sup></italic> or <italic>Ext1<sup>e2fl</sup></italic> in chondrocytes</td>
<td>6 to 10 weeks</td>
<td>100<sup><xref ref-type="table-fn" rid="table-fn3-0300985811398252">b</xref></sup></td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> C57BL/6-<italic>Ext2<sup>tm1Werb</sup></italic>
<sup><xref ref-type="bibr" rid="bibr91-0300985811398252">91</xref></sup></td>
<td>Targeted mutation of <italic>Ext2</italic>
</td>
<td>NA</td>
<td>28 (7/25)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">
<italic>OSTEOGENIC TUMORS: OSTEOMA</italic>
</td>
</tr>
<tr>
<td>B6C3F1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.06 (1/1,540)</td>
<td>0</td>
<td>0.13 (1/770)</td>
</tr>
<tr>
<td>CD1<sup><xref ref-type="bibr" rid="bibr63-0300985811398252">63</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.17 (3/1,781)</td>
<td>0.11 (1/891)</td>
<td>0.22 (2/890)</td>
</tr>
<tr>
<td rowspan="2">Crl:CD-1(ICR)<sup><xref ref-type="bibr" rid="bibr66-0300985811398252">66</xref></sup></td>
<td>Suspected to be retroviral (control mice)</td>
<td>55 to 97 weeks</td>
<td>3.2 (6/190)</td>
<td>1.1 (1/95)</td>
<td>5.3 (5/95)</td>
</tr>
<tr>
<td>Suspected to be retroviral (Sodium Flouride treated mice)</td>
<td>55 to 97 weeks</td>
<td>12.5 (34/272)</td>
<td>11 (15/136)</td>
<td>14 (19/136)</td>
</tr>
<tr>
<td>CF1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>5.5 (142/2,600)</td>
<td>4.4 (57/1,300)</td>
<td>6.5 (85/1,300)</td>
</tr>
<tr>
<td>CF1<sup><xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref></sup></td>
<td>Spontaneous</td>
<td>96 weeks, average</td>
<td>10 (67/668)</td>
<td>8.5 28/328)</td>
<td>11.5 (39/340)</td>
</tr>
<tr>
<td>CF1<sup><xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref></sup></td>
<td>Spontaneous (mice were treated with DDT or urethane)</td>
<td>NA</td>
<td>14.4 (479/3,319)</td>
<td>11.7 (208/1,763)</td>
<td>17.4 (271/1,556)</td>
</tr>
<tr>
<td>Han:NMRI<sup><xref ref-type="bibr" rid="bibr36-0300985811398252">36</xref></sup></td>
<td>Spontaneous</td>
<td>19 months</td>
<td>0.1 (1/900</td>
<td>0</td>
<td>0.1 (1/900</td>
</tr>
<tr>
<td>Him:OF1<sup><xref ref-type="bibr" rid="bibr36-0300985811398252">36</xref></sup></td>
<td>Suspected to be viral (etiology not convincingly established)</td>
<td>533 ± 98 days</td>
<td>51.8 (116/224)</td>
<td>50.9 (57/112)</td>
<td>52.7 (59/112)</td>
</tr>
<tr>
<td>NMRI<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr7-0300985811398252">7</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.16 (1/614)</td>
<td>0.16 (1/614)</td>
<td>0</td>
</tr>
<tr>
<td rowspan="2">OF-1<sup><xref ref-type="bibr" rid="bibr108-0300985811398252">108</xref></sup></td>
<td>Spontaneous (type C retroviral particles were observed in the tumors)</td>
<td>40 to 78 weeks</td>
<td>35 (35/100)</td>
<td>20 (10/50)</td>
<td>30 (15/50)</td>
</tr>
<tr>
<td>Spontaneous (mice were treated with Cyclosporine A and type C retroviral particles were observed in the tumors)</td>
<td>40 to 78 weeks</td>
<td>26.3 (79/300)</td>
<td>14.7 (22/150)</td>
<td>38 (57/150)</td>
</tr>
<tr>
<td colspan="6">
<italic>VASCULAR TUMORS: HEMANGIOMA</italic>
</td>
</tr>
<tr>
<td>BALB/c<sup><xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.95 (2/210)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">
<italic>MISCELLANEOUS TUMORS: OSSIFYING FIBROMA</italic>
</td>
</tr>
<tr>
<td>CD1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>CF1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>NMRI<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0300985811398252">
<p>
<sup>a</sup> Age of incidence as indicated in the original reference.</p>
</fn>
<fn id="table-fn3-0300985811398252">
<p>
<sup>b</sup> Number of tumor-bearing mice and mice examined by necropsy not available from the reference.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The Mouse Tumor Biology Database (<ext-link ext-link-type="uri" xlink:href="http://www.informatics.jax.org/">http://www.informatics.jax.org/</ext-link>, September 2010),<sup><xref ref-type="bibr" rid="bibr52-0300985811398252">52</xref></sup> Mouse Genome (<ext-link ext-link-type="uri" xlink:href="http://www.informatics.jax.org/">http://www.informatics.jax.org/</ext-link>, September 2010),<sup><xref ref-type="bibr" rid="bibr21-0300985811398252">21</xref></sup> and JAX Mice Database (<ext-link ext-link-type="uri" xlink:href="http://www.jaxmice.org/query/">http://www.jaxmice.org/query/</ext-link>, September 2010) at The Jackson Laboratory were used to verify information on tumor types, tumor frequencies, genes, alleles, and mouse strains. Tumor frequencies or comments pertaining to tumor frequencies that reference the Mouse Tumor Biology Database are identified in subscript as <sub>(MTB)</sub>.</p>
<p>Genes with a confirmed involvement in the pathogenesis of bone neoplasms in genetically engineered mouse models and genes known to significantly interact with the aforementioned genes were listed for gene network analysis. For performing the network analysis, each gene was assigned a hypothetical fold change score. If the loss or inactivation of a gene resulted in the development of a bone neoplasm in a mouse model, that gene was considered <italic>downregulated</italic> and assigned a hypothetical fold change score of –99 (eg, tumor suppressor genes). If the transgenic overexpression or dysregulated activation of a gene resulted in the development of a bone neoplasm in a mouse model, that gene was considered <italic>upregulated</italic> and assigned a hypothetical fold change score of 99 (eg, oncogenes). Ingenuity IPA Pathway Analysis Software (Redwood City, CA) was used for the gene network analysis. The list of genes is available in Supplementary <xref ref-type="table" rid="table3-0300985811398252">Table 3</xref>(available at <ext-link ext-link-type="uri" xlink:href="http://vet.sagepub.com/supplemental">http://vet.sagepub.com/supplemental</ext-link>).</p>
<table-wrap id="table3-0300985811398252" position="float">
<label>Table 3.</label>
<caption>
<p>Malignant Bone Tumors in Various Strains of Mice as Reported in the Literature</p>
</caption>
<graphic alternate-form-of="table3-0300985811398252" xlink:href="10.1177_0300985811398252-table3.tif"/>
<graphic alternate-form-of="table3-0300985811398252" xlink:href="10.1177_0300985811398252-table3a.tif"/>
<graphic alternate-form-of="table3-0300985811398252" xlink:href="10.1177_0300985811398252-table3b.tif"/>
<graphic alternate-form-of="table3-0300985811398252" xlink:href="10.1177_0300985811398252-table3c.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
</th>
<th>
</th>
<th align="center" colspan="3">Tumor Frequency, %</th>
</tr>
<tr>
<th>Mouse Strain</th>
<th>Tumorigenesis (Genotype if Applicable)</th>
<th>Age at Necropsy<sup><xref ref-type="table-fn" rid="table-fn4-0300985811398252">a</xref></sup></th>
<th>Both Sexes</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">
<italic>CARTILAGINOUS TUMORS: CHONDROSARCOMA</italic>
</td>
</tr>
<tr>
<td>B6C3F1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>110 weeks</td>
<td>NA</td>
<td>NA</td>
<td>0.13 (1)<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>ST/Eh<sup><xref ref-type="bibr" rid="bibr92-0300985811398252">92</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>C.129-<italic>Nfatc2<sup>tm1Glm</sup></italic>
<sup><xref ref-type="bibr" rid="bibr84-0300985811398252">84</xref></sup></td>
<td>
<italic>Nfatc2</italic> (<italic>Nfatp</italic>)</td>
<td>6 months</td>
<td>NA</td>
<td>100<sup><xref ref-type="table-fn" rid="table-fn6-0300985811398252">c</xref></sup></td>
<td>33<sup><xref ref-type="table-fn" rid="table-fn6-0300985811398252">c</xref></sup></td>
</tr>
<tr>
<td>Strain not specified, <italic>Tg(Gli2;ColIIA1-Trp53<sup>tm1Tyj</sup></italic>
<sup><xref ref-type="bibr" rid="bibr35-0300985811398252">35</xref></sup></td>
<td>Transgenic overexpression of <italic>Gli2</italic> combined with inactivation of <italic>Trp53</italic> (<italic>Trp53+/–</italic>) in chondrocytes</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">
<italic>OSTEOGENIC TUMORS: OSTEOSARCOMA</italic>
</td>
</tr>
<tr>
<td>Spontaneous</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> AKR/J<sup><xref ref-type="bibr" rid="bibr1-0300985811398252">1</xref></sup></td>
<td>Spontaneous</td>
<td>5 months</td>
<td>Single case</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> AKR/Ms<sup><xref ref-type="bibr" rid="bibr70-0300985811398252">70</xref></sup></td>
<td>Spontaneous (Type C retroviral particles were identified in the tumors)</td>
<td>300 days</td>
<td>NA</td>
<td>Single case</td>
<td>NA</td>
</tr>
<tr>
<td> B6CF1<sup><xref ref-type="bibr" rid="bibr27-0300985811398252">27</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> B6C3F1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.52 (8/1,540)</td>
<td>0.26 (2/770)</td>
<td>0.53 (6/770)</td>
</tr>
<tr>
<td> B6C3F1<sup><xref ref-type="bibr" rid="bibr104-0300985811398252">104</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.98 (5/5,065)</td>
<td>0.03 (1/2,543)</td>
<td>0.15 (4/2,522)</td>
</tr>
<tr>
<td> B6C3F1<sup><xref ref-type="bibr" rid="bibr9-0300985811398252">9</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.25 (1/400)</td>
<td>0.5 (1/200)</td>
<td>0</td>
</tr>
<tr>
<td> BALB/cCr<sup><xref ref-type="bibr" rid="bibr62-0300985811398252">62</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.03 (1/2,928)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> BALB/cCr<sup><xref ref-type="bibr" rid="bibr74-0300985811398252">74</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.05 (1/2,065)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> BALB/c<sup><xref ref-type="bibr" rid="bibr27-0300985811398252">27</xref></sup></td>
<td>Spontaneous</td>
<td>541 ± 297 days</td>
<td>0.08 (2/2,376)</td>
<td>NA</td>
<td>0.08 (2/2,376)</td>
</tr>
<tr>
<td> BALB/c<sup><xref ref-type="bibr" rid="bibr27-0300985811398252">27</xref></sup></td>
<td>Spontaneous (mice were treated with 2-acetylaminofluorene)</td>
<td>581 ± 149 days</td>
<td>0.06 (14/21,816)</td>
<td>NA</td>
<td>0.06 (14/21,816)</td>
</tr>
<tr>
<td> C3Hf/Sed;CB17-<italic>Prkdc<sup>scid</sup></italic>
<sup><xref ref-type="bibr" rid="bibr39-0300985811398252">39</xref></sup></td>
<td>Spontaneous</td>
<td>17 months</td>
<td>NA</td>
<td>NA</td>
<td>Single case</td>
</tr>
<tr>
<td> C57BL/6J<sup><xref ref-type="bibr" rid="bibr14-0300985811398252">14</xref></sup></td>
<td>Spontaneous</td>
<td>5 weeks</td>
<td>NA</td>
<td>Single case</td>
<td>NA</td>
</tr>
<tr>
<td> C57BL/6J-<italic>Ptpn6<sup>mev</sup></italic>
<sup><xref ref-type="bibr" rid="bibr45-0300985811398252">45</xref></sup></td>
<td>Spontaneous</td>
<td>757 days</td>
<td>NA</td>
<td>NA</td>
<td>Single case</td>
</tr>
<tr>
<td> C57BL/Icrf<sup><xref ref-type="bibr" rid="bibr26-0300985811398252">26</xref></sup></td>
<td>Spontaneous</td>
<td>12–31 months</td>
<td>0.16 (7/4,381)</td>
<td>0</td>
<td>0.41 (7/1,707)</td>
</tr>
<tr>
<td> CD-1<sup><xref ref-type="bibr" rid="bibr63-0300985811398252">63</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.22 (4/1,781)</td>
<td>0.22 (2/891)</td>
<td>0.22 (2/890)</td>
</tr>
<tr>
<td> CD-1 HaM/ICR<sup><xref ref-type="bibr" rid="bibr72-0300985811398252">72</xref></sup></td>
<td>Spontaneous</td>
<td>4–20 months</td>
<td>0.6 (6/1,000)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> CF-1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.12 (3/3,600)</td>
<td>0.15 (2/1,300)</td>
<td>0.8 (1/1,300)</td>
</tr>
<tr>
<td> CF-1<sup><xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref></sup></td>
<td>Spontaneous (a subset of mice were treated with DDT or urethane)</td>
<td>49–130 weeks</td>
<td>0.37 (15/3,987)</td>
<td>0.24 (5/2,091)</td>
<td>0.53 (10/1,896)</td>
</tr>
<tr>
<td> Han:NMRI<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr85-0300985811398252">85</xref></sup></td>
<td>Spontaneous</td>
<td>11–33 months</td>
<td>1.1 (10/900)</td>
<td>NA</td>
<td>1.1 (10/900)</td>
</tr>
<tr>
<td> NMRI<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr7-0300985811398252">7</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>0.41 (5/1,205)</td>
<td>0.33 (2/614)</td>
<td>0.51 (3/591)</td>
</tr>
<tr>
<td> NMRI/Nhg<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.75 (15/2,002)</td>
</tr>
<tr>
<td> NOD/ShiLtJ<sup><xref ref-type="bibr" rid="bibr50-0300985811398252">50</xref></sup></td>
<td>Spontaneous</td>
<td>66–247 days (129.6)</td>
<td>10.8 (39/361)</td>
<td>8.9 (14/158)</td>
<td>12.3 (25/202)</td>
</tr>
<tr>
<td> NOD.SCID substrains<sup><xref ref-type="bibr" rid="bibr50-0300985811398252">50</xref></sup></td>
<td>Spontaneous</td>
<td>49–537 days (161.2)</td>
<td>3.9 (16/407)</td>
<td>3.1 (4/129)</td>
<td>5.5 (12/218)</td>
</tr>
<tr>
<td> NZBR/BI<sup><xref ref-type="bibr" rid="bibr29-0300985811398252">29</xref></sup></td>
<td>Spontaneous</td>
<td>340–593 days</td>
<td>3.67 (4/109)</td>
<td>6.98 (3/43)</td>
<td>1.5 (1/66)</td>
</tr>
<tr>
<td> NZBR/BI<sup><xref ref-type="bibr" rid="bibr29-0300985811398252">29</xref></sup></td>
<td>Spontaneous (mice were treated with paraffin)</td>
<td>270–391 days</td>
<td>6.12 (3/49)</td>
<td>6.12 (3/49)</td>
<td>NA</td>
</tr>
<tr>
<td> Swiss Webster (CFW)<sup><xref ref-type="bibr" rid="bibr76-0300985811398252">76</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>1.5 (1/66)</td>
<td>0</td>
<td>2.6 (1/38)</td>
</tr>
<tr>
<td> SWR/J<sup><xref ref-type="bibr" rid="bibr81-0300985811398252">81</xref></sup></td>
<td>Spontaneous</td>
<td>22 months</td>
<td>0.14 (1/671)</td>
<td>0</td>
<td>0.25 (1/402)</td>
</tr>
<tr>
<td>Hormonally induced</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> BALB/c<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of diethylstilbestrol</td>
<td>NA</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> B6CF1<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of diethylstilbestrol</td>
<td>NA</td>
<td>2<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> B6CF2<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of diethylstilbestrol</td>
<td>NA</td>
<td>2<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> C3H/HeJ<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of 17β estradiol or diethylstilbestrol (mice had a high titer of Mouse Mammary Tumor Virus)</td>
<td>NA</td>
<td>3<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0</td>
<td>3<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> C3HeB/FeJ<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of diethylstilbestrol (mice had a low titer of Mouse Mammary Tumor Virus)</td>
<td>NA</td>
<td>3<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0</td>
<td>3<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> C3H/HeN<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of diethylstilbestrol (mice had a high titer of Mouse Mammary Tumor Virus)</td>
<td>NA</td>
<td>2<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0</td>
<td>2<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> C57BL/6J<sup><xref ref-type="bibr" rid="bibr34-0300985811398252">34</xref></sup></td>
<td>Dietary administration of diethylstilbestrol</td>
<td>NA</td>
<td>9<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>4<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>5<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>Radiation induced</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> C3101F1<sup><xref ref-type="bibr" rid="bibr64-0300985811398252">64</xref></sup></td>
<td>Induced by administration of radionuclides (<sup>224</sup>Ra or <sup>227</sup>Th); type A and/or type C retroviral particles were isolated from tumors</td>
<td>8–20 months</td>
<td>26<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>7<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>19<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> CBA/H<sup><xref ref-type="bibr" rid="bibr4-0300985811398252">4</xref></sup></td>
<td>Administration of the bone seeking radionuclide Strontium-90</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> Crl:CD-1(ICR)<sup><xref ref-type="bibr" rid="bibr71-0300985811398252">71</xref></sup></td>
<td>External irradiation of the back with <sup>90</sup>Sr-<sup>90</sup>Y β-rays</td>
<td>NA</td>
<td>23<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> NMRI<sup><xref ref-type="bibr" rid="bibr64-0300985811398252">64</xref></sup></td>
<td>Induced by administration of radionuclides (<sup>223</sup>Ra, <sup>224</sup>Ra, or <sup>227</sup>Th); type A and/or type C retroviral particles were isolated from tumors</td>
<td>11–27 months</td>
<td>26<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>25<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>Virally induced</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> BALB/cCrl<sup><xref ref-type="bibr" rid="bibr73-0300985811398252">73</xref></sup></td>
<td>Induced by intramedullary inoculation of Moloney murine sarcoma virus into the proximal tibial metaphysis</td>
<td>NA</td>
<td>100 (66/66)</td>
<td>NA</td>
<td>100 (66/66)</td>
</tr>
<tr>
<td> C3H/BiDa<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup></td>
<td>Intraperitoneal inoculation of mouse polyomavirus in neonates</td>
<td>188 days</td>
<td>17 (18/106)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> CzechII/EiJ<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup></td>
<td>Intraperitoneal inoculation of mouse polyoma virus in neonates</td>
<td>190 days</td>
<td>86.8 (33/38)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> C3CZF1<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup></td>
<td>Intraperitoneal inoculation of mouse polyoma virus in neonates</td>
<td>NA</td>
<td>75 (12/16)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> CF1/Anl<sup><xref ref-type="bibr" rid="bibr23-0300985811398252">23</xref></sup></td>
<td>Spontaneous retroviral (FBJ virus)</td>
<td>260 days</td>
<td>NA</td>
<td>Single case</td>
<td>NA</td>
</tr>
<tr>
<td> N:NIH(s) (NIH Swiss)<sup><xref ref-type="bibr" rid="bibr105-0300985811398252">105</xref></sup></td>
<td>Intraperitoneal inoculation of FBJ virus in neonates</td>
<td>26–145 days<sup><xref ref-type="table-fn" rid="table-fn7-0300985811398252">d</xref></sup></td>
<td>55.17 (80/145)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Genetically engineered</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> B6;CBA;Him:OF-1-Tg(<italic>H2-c-fosLTR</italic>)<sup><xref ref-type="bibr" rid="bibr31-0300985811398252">31</xref></sup></td>
<td>Transgenic expression of <italic>c-fos</italic> under the <italic>H-2kb class I MHC</italic> promoter</td>
<td>6 months (heterozygotes), 10–12 weeks (homozygotes)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Genetically engineered: SV40 Tag</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> B6.129S- <italic>B2m<sup>tm1Jae</sup></italic>;B6-Tg(Amy1 TAg)501Knw/J<sup><xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref></sup></td>
<td>SV40 T antigen</td>
<td>300–795 days</td>
<td>70.8 (51/72)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> B6.129S2- <italic>CD4<sup>tm1Knw</sup></italic>;B6-Tg(Amy1 TAg)501Knw/J<sup><xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref></sup></td>
<td>SV40 T antigen</td>
<td>165–585 days</td>
<td>63.3 (93/147)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> BDF1-Tg(<italic>hsp70SV40Tag</italic>)<sup><xref ref-type="bibr" rid="bibr106-0300985811398252">106</xref></sup></td>
<td>SV40 T-antigen</td>
<td>31 weeks, homozygous; 46 weeks, hemizygous</td>
<td>9<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>7<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>2<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td> C57BL/6J-Tg(Amy1TAg)501Knw/J<sup><xref ref-type="bibr" rid="bibr51-0300985811398252">51</xref></sup></td>
<td>SV40 T antigen</td>
<td>15 months</td>
<td>66.7 (20/30)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> C57BL/6J-Tg(Amy1TAg)501Knw/J<sup><xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref></sup></td>
<td>SV40 T antigen</td>
<td>240–570 days</td>
<td>69.1 (112/162)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> C57BL/6J-Tg(WAPTag)3Knw/J<sup><xref ref-type="bibr" rid="bibr40-0300985811398252">40</xref></sup></td>
<td>SV40 T antigen</td>
<td>6 months</td>
<td>98.5 (67/68)</td>
<td>100 (37/37)</td>
<td>96.8 (30/31)</td>
</tr>
<tr>
<td> Strain not specified,  Tg(<italic>mP1-SV40Tag</italic>)<sup><xref ref-type="bibr" rid="bibr5-0300985811398252">5</xref></sup></td>
<td>SV40 T antigen fused to the mouse Protamine gene</td>
<td>NA</td>
<td>4<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Genetically engineered: <italic>Nf2</italic>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> 129S2- <italic>Nf2<sup>tm1Tyj</sup></italic>
<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup></td>
<td>Targeted mutation of <italic>Nf2</italic> (<italic>Nf2+/–</italic>)</td>
<td>18.7 months, females; 23 months, males</td>
<td>76 (28/37)</td>
<td>67 (12/18)</td>
<td>84 (16/19)</td>
</tr>
<tr>
<td> (C57BL/6 x 129S2-<italic>Nf2<sup>tm1Tyj</sup></italic>) F1<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup></td>
<td>Targeted mutation of <italic>Nf2</italic> (<italic>Nf2+/–</italic>)</td>
<td>NA</td>
<td>63 (62/99)</td>
<td>56 (38/68)</td>
<td>77 (24/31)</td>
</tr>
<tr>
<td> (C57BL/6 x 129S2-<italic>Nf2<sup>tm1Tyj</sup></italic>) F2<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup></td>
<td>Targeted mutation of <italic>Nf2</italic> (<italic>Nf2+/–</italic>)</td>
<td>NA</td>
<td>51 (23/45)</td>
<td>60 (9/15)</td>
<td>47 (14/30)</td>
</tr>
<tr>
<td>Genetically engineered: <italic>Trp53</italic>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> B6.129S1-<italic>Trp53<sup>tm1Brd</sup></italic>
<sup><xref ref-type="bibr" rid="bibr18-0300985811398252">18</xref></sup></td>
<td>Targeted germline mutation of <italic>Trp53</italic> (<italic>Trp53</italic>–/–)</td>
<td>16 weeks</td>
<td>2.85 (1/35)</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>NA</td>
</tr>
<tr>
<td> B6.129S1-<italic>Trp53<sup>tm1Brd</sup></italic>
<sup><xref ref-type="bibr" rid="bibr18-0300985811398252">18</xref></sup></td>
<td>Targeted germline mutation of <italic>Trp53</italic> (chimera)</td>
<td>60 weeks</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>NA</td>
</tr>
<tr>
<td> 129S-<italic>Trp53<sup>tm1Brd</sup></italic>
<sup><xref ref-type="bibr" rid="bibr33-0300985811398252">33</xref></sup></td>
<td>Targeted germline mutation of <italic>Trp53</italic> (<italic>Trp53</italic>–/–)</td>
<td>NA (5 weeks for tumors in general)</td>
<td>6.89 (2/29)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> B6.129S1-<italic>Trp53<sup>tm1Brd</sup></italic>
<sup><xref ref-type="bibr" rid="bibr33-0300985811398252">33</xref></sup></td>
<td>Targeted germline mutation of <italic>Trp53</italic> (<italic>Trp53</italic>–/–)</td>
<td>NA</td>
<td>3.33 (2/60)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> B6.129S2- <italic>Trp53<sup>tm1Tyj</sup></italic>
<sup><xref ref-type="bibr" rid="bibr44-0300985811398252">44</xref></sup></td>
<td>Targeted germline mutation of <italic>Trp53</italic> (<italic>Trp53</italic>–/–)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> B6.129S2- <italic>Trp53<sup>tm1Tyj</sup></italic>
<sup><xref ref-type="bibr" rid="bibr44-0300985811398252">44</xref></sup></td>
<td>Targeted germline mutation of <italic>Trp53</italic> (<italic>Trp53</italic>+/–)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td> 129S2- <italic>Nf2<sup>tm1Tyj</sup>Trp53<sup>tm1Ty</sup></italic>
<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup> and  (C57BL/6 x 129S2-<italic>Nf2<sup>tm1Tyj</sup>Trp53<sup>tm1Tyj</sup></italic>) F1<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup></td>
<td>Targeted mutations of <italic>Nf2</italic> and <italic>Trp53</italic> in cis - both on Chromosome 11 (<italic>Nf2+/–Trp53+/–</italic>)</td>
<td>NA</td>
<td>77 <sup>c</sup></td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td rowspan="9"> Mixed C57BL/6, 129 FVB/N  background, <italic>Rb1<sup>tm1TyJ</sup>Trp53<sup>tm1TyJ</sup>  Osx1GFPCre</italic>
<sup><xref ref-type="bibr" rid="bibr101-0300985811398252">101</xref></sup></td>
<td>Osteoblast restricted deletion of <italic>Trp53</italic> and/or <italic>Rb</italic>
</td>
<td colspan="4">See below for number of tumors and penetrance by genotype</td>
</tr>
<tr>
<td>
<italic>Trp53</italic>+/–, <italic>Rb</italic>+/+</td>
<td>338</td>
<td>8.33 (1/11)</td>
<td>0</td>
<td>8.33 (1/11)</td>
</tr>
<tr>
<td>
<italic>Trp53</italic>–/–, <italic>Rb</italic>+/+</td>
<td>292.8 ± 21.8</td>
<td>100 (5/5)</td>
<td>60 (3/5)</td>
<td>40 (2/5)</td>
</tr>
<tr>
<td>
<italic>Trp53</italic>+/+, <italic>Rb</italic>+/–</td>
<td>
</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>
<italic>Trp53</italic>+/+, <italic>Rb</italic>–/–</td>
<td>
</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>
<italic>Trp53</italic>+/–, <italic>Rb</italic>+/–</td>
<td>198.3 ± 22</td>
<td>30 (13)<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>8<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>5<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>
<italic>Trp53</italic>+/–, <italic>Rb</italic>–/–</td>
<td>177 ± 14.4</td>
<td>77.8 (13)<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>6<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>7<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>
<italic>Trp53</italic>–/–, <italic>Rb</italic>+/–</td>
<td>158.4 ± 10.2</td>
<td>100 (27/27)</td>
<td>19<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>8<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>
<italic>Trp53</italic>–/–, <italic>Rb</italic>–/–</td>
<td>127.9 ± 3.4</td>
<td>100 (24/24)</td>
<td>15<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>9<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td rowspan="6"> Mixed C57BL/6, 129 FVB/N back ground, <italic>Rb1<sup>tm1TyJ</sup>Trp53<sup>tm1Ty J</sup>Osx1GFPCre</italic>
<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref></sup><break/>
</td>
<td>Conditional inactivation of <italic>Trp53</italic> and/or <italic>Rb</italic> in osteoblast precursor cells</td>
<td colspan="4">See below for tumor frequency by genotype</td>
</tr>
<tr>
<td>
<italic>Trp53–/–</italic>
</td>
<td>281 ± 55 days</td>
<td>100 (25/25)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>
<italic>Rb+/–, Trp53+/–</italic>
</td>
<td>299 ± 84 days</td>
<td>100 (16/16)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>
<italic>Rb –/–, Trp53+/–</italic>
</td>
<td>251 ± 87 days</td>
<td>94.4 (17/18)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>
<italic>Rb +/–, Trp53–/–</italic>
</td>
<td>207 ± 33 days</td>
<td>100 (21/21)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>
<italic>Rb –/–, Trp53–/–</italic>
</td>
<td>147 ± 31 days</td>
<td>65.12 (28/43)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">
<italic>VASCULAR TUMORS: HEMANGIOSARCOMA</italic>
</td>
</tr>
<tr>
<td>B6C3F1<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></td>
<td>Spontaneous</td>
<td>NA</td>
<td>11<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0.78 (6)<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
<td>0.65 (5)<sup><xref ref-type="table-fn" rid="table-fn5-0300985811398252">b</xref></sup></td>
</tr>
<tr>
<td>NZB<sup><xref ref-type="bibr" rid="bibr41-0300985811398252">41</xref></sup></td>
<td>Spontaneous</td>
<td>12 months</td>
<td>NA</td>
<td>Single case</td>
<td>NA</td>
</tr>
<tr>
<td>C3H/HeH<sup><xref ref-type="bibr" rid="bibr4-0300985811398252">4</xref></sup></td>
<td>Administration of the bone seeking radionuclide Strontium-90</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>CBA/H<sup><xref ref-type="bibr" rid="bibr4-0300985811398252">4</xref></sup></td>
<td>Administration of the bone seeking radionuclide Strontium-90</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">
<italic>HEMATOPOIETIC TUMORS: MULTIPLE MYELOMA</italic>
</td>
</tr>
<tr>
<td>C57BL/KaLwRij<sup><xref ref-type="bibr" rid="bibr82-0300985811398252">82</xref></sup></td>
<td>Spontaneous</td>
<td>&gt; 2 years</td>
<td>0.5<sup><xref ref-type="table-fn" rid="table-fn6-0300985811398252">c</xref></sup></td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>C57BL/6J-Tg(<italic>Eμ-Xbp-1</italic>)<sup><xref ref-type="bibr" rid="bibr7-0300985811398252">7</xref></sup></td>
<td>Overexpression of <italic>Xbp-1</italic>
</td>
<td>14–24 months</td>
<td>26 (8/35)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>C57BL/6J-Tg(<italic>Vk*Myc</italic>)<sup><xref ref-type="bibr" rid="bibr13-0300985811398252">13</xref></sup></td>
<td>Mutant <italic>Myc</italic> transgene (<italic>Vk*Myc</italic>)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td colspan="6">
<italic>TUMORS OF UNCERTAIN HISTOGENESIS: SYNOVIAL SARCOMA</italic>
</td>
</tr>
<tr>
<td>B6;129X1-Tg(<italic>SYT-SSX</italic>)<sup><xref ref-type="bibr" rid="bibr32-0300985811398252">32</xref></sup></td>
<td>Conditional expression of human <italic>SYT-SSX</italic> fusion transgene in <italic>Myf5</italic> expressing myoblasts</td>
<td>3–5 months</td>
<td>100 (18/18)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0300985811398252">
<p>
<sup>a</sup> Age of incidence as indicated in the original reference.</p>
</fn>
<fn id="table-fn5-0300985811398252">
<p>
<sup>b</sup> Number of mice examined by necropsy is not available from the reference.</p>
</fn>
<fn id="table-fn6-0300985811398252">
<p>
<sup>c</sup> Numbers of tumor bearing mice and mice examined by necropsy are not available from the reference.</p>
</fn>
<fn id="table-fn7-0300985811398252">
<p>
<sup>d</sup> Induction time: time to appearance of the neoplasm after inoculation with the virus (at 1 to 2 days of age).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section2-0300985811398252">
<title>Results</title>
<sec id="section3-0300985811398252">
<title>Comparison of Classification Schemes</title>
<p>The <italic>WHO Classification of Bone Tumors</italic> in humans<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref></sup> broadly categorizes tumors as <italic>cartilage</italic>, <italic>osteogenic</italic>, <italic>giant</italic>
<italic>cell</italic>, <italic>notochordal</italic>, <italic>vascular</italic>, <italic>smooth</italic>
<italic>muscle</italic>, <italic>lipogenic</italic>, <italic>neural</italic>, <italic>miscellaneous</italic>, <italic>fibrogenic</italic>, <italic>fibrohistiocytic</italic>, <italic>primitive</italic>
<italic>neuroectodermal</italic>, and <italic>hematopoietic</italic>, as well as <italic>miscellaneous lesions</italic> and <italic>joint lesions</italic>. Synovial sarcoma is not included under joint lesions or other categories in this scheme because of its ambiguous histogenesis.<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref></sup> The <italic>WHO Classification of Bone Tumors</italic> in humans is also used for the mouse pathology ontology (<ext-link ext-link-type="uri" xlink:href="http://eulep.pdn.cam.ac.uk/Pathology_Ontology/index.php">http://eulep.pdn.cam.ac.uk/Pathology_Ontology/index.php</ext-link>), a system for the histopathology of genetically engineered mice in the European mutant mouse pathology database, Pathbase (<ext-link ext-link-type="uri" xlink:href="http://www.pathbase.net">http://www.pathbase.net</ext-link>).</p>
<p>The <italic>Histological Classification of Bone and Joint Tumors of Domestic Animals</italic>
<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup> broadly categorizes them as benign tumors, malignant tumors, and tumorlike lesions. Malignant tumors are subcategorized as central tumors, peripheral tumors, joint tumors, miscellaneous tumors, and tumors of bone marrow.<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup></p>
<p>The most commonly used scheme for classification of mouse bone tumors is the one detailed in the <italic>International Classification of Rodent Tumors: The Mouse.</italic>
<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup> Tumors of the skeletal system listed in this scheme include osteoma, osteosarcoma, osteofibroma, ossifying fibroma, chondroma, chondrosarcoma, and synovial sarcoma.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup> This classification scheme is disparate with extant WHO classifications of bone tumors in humans<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref></sup> and domestic animals,<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup> as well as with some of the descriptions of bone tumor types observed in laboratory mice.<sup><xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>
<xref ref-type="bibr" rid="bibr57-0300985811398252"/>
<xref ref-type="bibr" rid="bibr58-0300985811398252"/>
<xref ref-type="bibr" rid="bibr59-0300985811398252"/>
<xref ref-type="bibr" rid="bibr60-0300985811398252"/>–<xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref></sup> The mouse classification system describes (1) <italic>osteofibroma</italic> as being synonymous with <italic>osteoblastoma</italic> and (2) <italic>ossifying fibroma</italic> as being synonymous with <italic>cementifying fibroma</italic>.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup> Ossifying fibroma and osteofibroma are not described in the human World Health Organization classification scheme.<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref></sup> In classifications and descriptions of human bone tumors, osteoblastoma is considered similar to osteoid osteoma,<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> and the designation <italic>ossifying fibroma</italic> has been replaced by <italic>osteofibrous dysplasia</italic>.<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> The <italic>International Classification of Rodent Tumors: The Mouse</italic> does not consider intraosseous vascular neoplasms under tumors of the skeletal system.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref></sup> In some descriptions of mouse tumors, hemangioma and hemangioendothelioma are considered synonymous,<sup><xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref></sup> although the latter is considered synonymous with <italic>angiosarcoma</italic> in descriptions of human tumors.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup><xref ref-type="table" rid="table1-0300985811398252">Table 1</xref> compares and summarizes classification schemes for tumors of bones and joints; <xref ref-type="table" rid="table2-0300985811398252">Tables 2</xref> to 4 summarize details of these tumors, as reported in the literature and observed at The Jackson Laboratory.</p>
</sec>
<sec id="section4-0300985811398252">
<title>Cartilaginous Tumors</title>
<sec id="section5-0300985811398252">
<title>Osteochondroma</title>
<p>Osteochondromas are benign, cartilage-capped, partially ossified tumors that are also known as <italic>exostoses</italic>. They are typically reminiscent of an epiphyseal plate rotated 90° to the long axis of bone, given that they arise from the surface of an endochondral bone adjacent to a physis and are attached to the underlying skeleton by a bony stalk. Histologically, osteochondromas consist of chondrocytes arranged in a manner similar to that in epiphyses.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Spontaneous osteochondromas are the most common benign bone tumor in humans<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> and are reported in cats, dogs, and horses. They are extremely rare in laboratory mice<sup><xref ref-type="bibr" rid="bibr56-0300985811398252">56</xref></sup> and were reported in B6C3F1 mice (0.03% frequency in males).<sup><xref ref-type="bibr" rid="bibr104-0300985811398252">104</xref></sup> A single osteochondroma was found in a WBB6F1/J-<italic>Kit<sup>W</sup>/Kit<sup>W-v</sup>/J</italic> mouse at The Jackson Laboratory.</p>
</sec>
<sec id="section7-0300985811398252">
<title>Chondroma</title>
<p>Chondromas are benign tumors of chondrocytes consisting mostly of mature hyaline cartilage. They are typically circumscribed, encapsulated, slow growing, expansile, and smooth to nodular, and they usually occur in bones of enchondral origin. They can arise within the medullary cavity, where they are known as <italic>enchondromas</italic>, or on the surface of bone, where they are known as <italic>periosteal</italic> or <italic>juxtacortical chondromas</italic>. Histologically, chondromas consist of nodular aggregates of well-differentiated chondrocytes with little to no cellular and nuclear pleomorphism (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 1, 2</xref>).<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Spontaneous chondromas are extremely rare in laboratory mice.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr78-0300985811398252">78</xref><xref ref-type="bibr" rid="bibr79-0300985811398252"/>–<xref ref-type="bibr" rid="bibr80-0300985811398252">80</xref></sup> Chondromas were reported in C57BL/10J (0.1% frequency in females),<sup><xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref>,<xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup> and a single case was found in a NOD.129P2(B6)-<italic>B2m<sup>tm1Unc</sup></italic>/J mouse (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 1, 2</xref>) at The Jackson Laboratory.</p>
<fig id="fig1-0300985811398252" position="float">
<caption>
<p><bold>Figure 1.</bold> Cranium; NOD.129P2(B6)-<italic>B2m<sup>tm1Unc</sup></italic>/J mouse. There is a chondroma (Ch) arising from the squamosal bone. Note the circumscribed, noninvasive nature of the well-differentiated cartilaginous neoplasm. HE.</p>
<p>
<bold>Figure 2.</bold> Cranium; NOD.129P2(B6)-<italic>B2m<sup>tm1Unc</sup></italic>/J mouse. Higher magnification of the chondroma in Fig. 1 illustrates an orderly proliferation of well-differentiated chondrocytes (Ch) with a paucity of mitotic figures. HE.</p>
<p>
<bold>Figure 3.</bold> Hip joint, C57BL/6J mouse. There is a chondrosarcoma (Ch) arising from the coxofemoral articulation. Note the infiltrative nature of the well-differentiated cartilaginous neoplasm. HE.</p>
<p>
<bold>Figure 4.</bold> Hip joint, C57BL/6J mouse. Higher magnification of the chondrosarcoma in Fig. 3 illustrates proliferating chondrocytes (Ch) within a hyaline matrix. There is a mitotic figure (arrowhead). HE.</p>
<p>
<bold>Figure 5.</bold> Head; C57BL/6J mouse. There is a circumscribed bony neoplasm (osteoma) arising from the cranium.</p>
<p>
<bold>Figure 6.</bold> Cranium; C57BL/6J mouse. There is an osteoma (Os) arising from the cranium. Note the noninvasive proliferation of well-differentiated mature bone. HE.</p>
<p>
<bold>Figure 7.</bold> Cranium; C57BL/6J mouse. Higher magnification of the osteoma in Fig. 6 illustrates a benign proliferation of well-differentiated mature bone (Mb) with elements of bone marrow (arrowhead). HE.</p>
<p>
<bold>Figure 8.</bold> Body; NOD.NON-<italic>Thy<sup>1a</sup></italic>/J mouse. There is an infiltrative bony neoplasm (osteosarcoma) involving skeletal and soft tissues of the left forelimb.</p>
<p>
<bold>Figure 9.</bold> Cranium, AKR/J mouse. There is an osteosarcoma (Os) arising from the maxilla. Note the disorderly proliferation of less-differentiated bone and the absence of bone marrow within the neoplasm. HE.</p>
<p>
<bold>Figure 10.</bold> Cranium, AKR/J mouse. Higher magnification of the osteosarcoma (Os) in Fig. 9 illustrates haphazardly arranged spindloid cells in an eosinophilic matrix. Note the focus of mineralized osteoid (arrowhead). HE.</p>
<p>
<bold>Figure 11.</bold> Right hind limb, NOD/ShiLtJ mouse. There is an osteosarcoma (Os) arising from the os coxa. Note the highly cellular and disorderly proliferation of osteoblasts. HE.</p>
<p>
<bold>Figure 12.</bold> Right hind limb, NOD/ShiLtJ mouse. Higher magnification of the osteosarcoma in Fig. 11 illustrates osteoid (arrowhead) embedded within sheets of polygonal to ovoid neoplastic osteoblasts. HE.</p>
<p>
<bold>Figure 13.</bold> Left hind limb, NOD.Cg-<italic>Prkdc<sup>scid</sup>I12rg<sup>tm1Wjl</sup></italic>/SzJ mouse. There is a hemangiosarcoma (He) arising within the femur. Note the cavernous blood-filled spaces that obliterate medullary architecture. HE.</p>
<p>
<bold>Figure 14.</bold> Left hind limb, NOD.129P2(B6)-<italic>B2m<sup>tm1Unc</sup></italic>/J mouse. Higher magnification of the hemangiosarcoma in Fig. 13 illustrates haphazardly oriented vascular channels (arrowhead) lined by neoplastic endothelial cells (En). HE.</p>
<p>
<bold>Figure 15.</bold> Right hind limb; NONcNZO10/LtJ mouse. There is an ossifying fibroma (Of) surrounding the metatarsal bone. Note the expansile neoplasm consisting of a modestly cellular fibrous portion and mature osseous elements mostly toward the periphery. HE.</p>
<p>
<bold>Figure 16.</bold> Right hind limb; NONcNZO10/LtJ mouse. Higher magnification of the ossifying fibroma in Fig. 15 illustrates trabecular bone (Tb) embedded in a fibrous stroma (Fs). HE.</p>
</caption>
<graphic xlink:href="10.1177_0300985811398252-fig1.tif"/>
</fig>
</sec>
<sec id="section8-0300985811398252">
<title>Chondromyxoid fibroma</title>
<p>Chondromyxoid fibromas are benign cartilaginous tumors that typically involve the metaphyses of long bones. Histologically, chondromyxoid fibromas are usually lobulated, consisting of nodules of poorly formed hyaline cartilage mixed with variable amounts of myxoid matrix delinated by fibrous septae.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref>,<xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref>,<xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup> Chondromyxoid fibromas are extremely rare in humans,<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> domestic animals,<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup> and mice and were reported in C57BL/10J mice (0.04% frequency in males).<sup><xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref>,<xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup></p>
</sec>
<sec id="section9-0300985811398252">
<title>Chondrosarcoma</title>
<p>Chondrosarcomas are malignant cartilaginous neoplasms that arise de novo in bone or undergo malignant transformation within a preexisting benign cartilaginous tumor. They are typically expansile and sometimes lobulated, and they more commonly involve flat bones than long bones in most species. They have also been reported to arise in locations with extraskeletal cartilage, such as the larynx in humans and mice. Chondrosarcomas may arise from the medullary cavity (central chondrosarcoma) or periosteum (peripheral chondrosarcoma), with the former being more common. Histologically, chondrosarcomas are often lobulated, consisting of different proportions of hyaline or myxoid cartilage composed of chondrocytes that vary in cytologic atypia, mitotic activity, and degree of differentiation (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 3, 4</xref>). They primarily produce chondroid and fibrillar matrix but rarely osteoid. However, occasional chondrosarcomas may contain reactive or metaplastic bone matrix.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Chondrosarcoma is the third-most common malignancy of bone in humans, after myeloma and osteosarcoma,<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> and it is reported in cats, dogs, and sheep<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref></sup> but is extremely rare in mice.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>–<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref></sup> Spontaneous chondrosarcomas were reported in B6C3F1 mice (0.13% frequency in females),<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup> in C57BL/10J mice (0.03% frequency in females),<sup><xref ref-type="bibr" rid="bibr99-0300985811398252">99</xref>,<xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup> and in a ST/Eh mouse (single case)<sup><xref ref-type="bibr" rid="bibr92-0300985811398252">92</xref></sup> and observed in a 325 day-old male C57BL/6J mouse (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 3</xref>, 4) at The Jackson Laboratory.</p>
</sec>
</sec>
<sec id="section10-0300985811398252">
<title>Osteogenic Tumors</title>
<sec id="section11-0300985811398252">
<title>Osteoma</title>
<p>Osteomas are rare benign tumors of osteoblasts composed of mature well-differentiated bone with a predominantly woven arrangement. They are typically solitary, dense, and smooth, and they preferentially arise from the periosteal surface and merge with underlying cortical bone. Osteomas most commonly occur in bones of the skull in most species (<xref ref-type="fig" rid="fig1-0300985811398252">Fig. 5</xref>). An osteoma may rarely be seen on the surface of a long bone. Histologically, osteomas are composed of dense coalescing spicules and trabeculae of bone lined by osteoblasts and osteoclasts. Fatty or hematopoietic marrow may be present within the trabeculae (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 6, 7</xref>). The intertrabecular connective tissue is composed of spindle-shaped cells, and it becomes increasingly sparse as the tumor becomes more compact and sclerotic.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>-<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Spontaneous osteomas are rare in most strains of mice and seem to be more common in females than in males, with the difference being attributed partly to a female hormonal influence.
</p>
<p>Cases of spontaneous osteoma were documented in the following mice strains: AKR,<sup><xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref></sup> B6C3F1,<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr9-0300985811398252">9</xref></sup> C57BL/6NNia<sub>(MTB)</sub>, CBA/H<sub>(MTB)</sub>, CD-1,<sup><xref ref-type="bibr" rid="bibr63-0300985811398252">63</xref>,<xref ref-type="bibr" rid="bibr66-0300985811398252">66</xref>,<xref ref-type="bibr" rid="bibr72-0300985811398252">72</xref></sup> CF-1,<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref>,<xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref></sup> CFW/CarWHanJena<sub>(MTB)</sub>, NMRI<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr7-0300985811398252">7</xref></sup> NZO/Bl<sub>(MTB)</sub>, Him:OF1,<sup><xref ref-type="bibr" rid="bibr36-0300985811398252">36</xref></sup> and OF-1.<sup><xref ref-type="bibr" rid="bibr108-0300985811398252">108</xref></sup> CF-1, Him:OF1, and OF-1, which are genetically related outbred strains of mice and have the highest documented frequency of osteomas among all mouse strains.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref></sup> The reported frequency of spontaneous osteomas in CF-1 mice was 5.5% in one study<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup> (4.4% in males and 6.5% in females) and 10% in another (8.5% in males and 11.5% in females).<sup><xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref></sup> In the latter, the combined average age of occurrence for both sexes was 96 weeks.<sup><xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref></sup> Spontaneous osteomas are quite rare in other strains, with frequencies ranging from 0.02 to 0.20% in various reports.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup> In one study, a frequency of 0.13% was observed in female B6C3F1 mice (1 case in 770 mice examined).<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref></sup></p>
<p>Reports exist of higher frequencies of osteomas with concurrent identification and isolation of retroviral particles.<sup><xref ref-type="bibr" rid="bibr61-0300985811398252">61</xref></sup> In a study on skeletal lesions of sodium fluoride toxicity in Crl:CD-1 (ICR) outbred mice, the reported frequency was 12.5% in sodium fluoride–treated mice (11% in males and 14% in females) and 3.2% in controls (1.1% in males and 5.3% in females) with a suspected retroviral etiology at 55 to 97 weeks of age.<sup><xref ref-type="bibr" rid="bibr66-0300985811398252">66</xref></sup> In a study on the carcinogenic potential of cyclosporine A in OF-1 mice, a 26.3% frequency was reported in cyclosporine-treated mice (14.7% in males and 38% in females), with 35% in controls (20% in males and 30% in females), at 40 to 78 weeks of age.<sup><xref ref-type="bibr" rid="bibr108-0300985811398252">108</xref></sup> Type C retroviral particles were identified in tumors from both groups, but an etiologic correlation was not conclusively established. In an aging study, Him:OF-1 mice were reported to have a frequency of 51.8% (50.9% in males and 52.7% in females) at 533 ± 98 days of age, and viruslike particles were seen on ultrastructural observation of tumor cells and necrotic tissues.<sup><xref ref-type="bibr" rid="bibr36-0300985811398252">36</xref></sup> Osteomas induced by neonatal administration of murine polyomavirus were documented in C3H/BiDa mice.<sup><xref ref-type="bibr" rid="bibr17-0300985811398252">17</xref></sup> At The Jackson Laboratory, osteomas were diagnosed in mice of strains A/J, C57BL/6J (<xref ref-type="fig" rid="fig1-0300985811398252">Fig. 5</xref>), DBA/2J, B6C3F1/J, C3.SW-<italic>H2<sup>b</sup></italic>/SnJ, and C57BL6/J-Tg(Amy1Tag)501Knw/J (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 6, 7</xref>)—one case in each strain, all in females.</p>
</sec>
<sec id="section13-0300985811398252">
<title>Osteosarcoma</title>
<p>Osteosarcomas are malignant mesenchymal neoplasms in which tumor cells typically produce osteoid or bony matrix.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr56-0300985811398252">56</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr60-0300985811398252">60</xref>,<xref ref-type="bibr" rid="bibr69-0300985811398252">69</xref>,<xref ref-type="bibr" rid="bibr75-0300985811398252">75</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref>,<xref ref-type="bibr" rid="bibr102-0300985811398252">102</xref></sup>They are typically invasive, and they frequently metastasize.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref><xref ref-type="bibr" rid="bibr56-0300985811398252"/>-<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr60-0300985811398252">60</xref>,<xref ref-type="bibr" rid="bibr75-0300985811398252">75</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref>,<xref ref-type="bibr" rid="bibr102-0300985811398252">102</xref></sup> Osteosarcomas most commonly arise within the medullary cavities of bones—particularly, the metaphyseal regions of long bones—and invade the adjacent cortex (<xref ref-type="fig" rid="fig1-0300985811398252">Fig. 8</xref>); these are referred to as <italic>central osteosarcomas</italic>. Osteosarcomas less commonly arise from the periosteum; these are called <italic>peripheral osteosarcomas</italic> and are of two types—namely, periosteal or parosteal (juxtacortical) osteosarcomas. Histologically, osteosarcomas consist of malignant osteoblasts, osteoclasts, or less differentiated mesenchymal cells that often form osteoid matrix (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 9, 10, 11, 12</xref>).<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Based on histologic and cytologic features, osteosarcomas are often subtyped as <italic>osteoblastic</italic>, <italic>osteoclastic</italic>, <italic>fibroblastic</italic>, <italic>chondroblastic</italic>, <italic>telangiectatic</italic>/<italic>vascular</italic>, <italic>mixed</italic>, or <italic>anaplastic</italic>.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup> With the exception of myeloma and lymphoma in humans, osteosarcoma is the most common primary bone tumor in most species.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref>,<xref ref-type="bibr" rid="bibr102-0300985811398252">102</xref></sup>Osteosarcomas rarely arise in extraskeletal soft tissues independent of adjacent bones.<sup><xref ref-type="bibr" rid="bibr24-0300985811398252">24</xref></sup></p>
<p>Osteosarcomas are the most commonly reported bone tumors in laboratory mice,<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr68-0300985811398252">68</xref>,<xref ref-type="bibr" rid="bibr69-0300985811398252">69</xref></sup> but the average frequency of spontaneous osteosarcomas in most strains of mice is relatively low<sub>(MTB)</sub>.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr56-0300985811398252">56</xref></sup> There have been single-case reports of osteosarcoma in a 5-month-old AKR/J male mouse,<sup><xref ref-type="bibr" rid="bibr1-0300985811398252">1</xref></sup> 300-day-old AKR/Ms mouse,<sup><xref ref-type="bibr" rid="bibr70-0300985811398252">70</xref></sup> 5-week-old C57BL/6J male mouse,<sup><xref ref-type="bibr" rid="bibr14-0300985811398252">14</xref></sup> 224-day-old C57BL/6J female mouse<sub>(MTB)</sub>,757-day-old C57BL/6J-<italic>Ptpn6<sup>mev</sup></italic>/<italic>Ptpn6<sup>mev</sup></italic>female mouse,<sup><xref ref-type="bibr" rid="bibr45-0300985811398252">45</xref></sup> and 17 month-old C3Hf/Sed;CB17-<italic>Prkdc<sup>scid</sup></italic>/<italic>Prkdc<sup>scid</sup></italic> female mouse.<sup><xref ref-type="bibr" rid="bibr39-0300985811398252">39</xref></sup> A recent study reported a relatively higher frequency of spontaneous osteosarcomas in NOD/ShiLtJ and NOD-derived mice at The Jackson Laboratory.<sup><xref ref-type="bibr" rid="bibr50-0300985811398252">50</xref></sup> Spontaneous osteosarcomas were also observed in mice of strains C3Hf/He (0.4% to 1.0% frequency in females)<sub>(MTB)</sub>, C57BL/6NNia (1.1% frequency)<sub>(MTB)</sub>, RF/Un (0.7% frequency)<sub>(MTB)</sub>, and SWR/J (0.6% frequency)<sub>(MTB)</sub>. The age of occurrence of osteosarcomas, as reported in various mouse strains, varied from 35 days (5 weeks) in a C57BL/6J male mouse<sup><xref ref-type="bibr" rid="bibr14-0300985811398252">14</xref></sup> to 31 months (more than 900 days) in C57BL/Icrf mice.<sup><xref ref-type="bibr" rid="bibr26-0300985811398252">26</xref></sup></p>
<p>Virally induced osteosarcomas were periodically reported, and most notable among them are the ones induced by retroviruses (Finkel Biskis Jenkins murine osteosarcoma virus and Moloney murine sarcoma virus)<sup><xref ref-type="bibr" rid="bibr23-0300985811398252">23</xref>,<xref ref-type="bibr" rid="bibr73-0300985811398252">73</xref>,<xref ref-type="bibr" rid="bibr77-0300985811398252">77</xref>,<xref ref-type="bibr" rid="bibr105-0300985811398252">105</xref></sup> and murine polyomavirus.<sup><xref ref-type="bibr" rid="bibr17-0300985811398252">17</xref>,<xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup> Periosteal chondro-osseous tumors resembling human parosteal osteosarcomas were induced in National Institutes of Health Swiss mice by neonatal intraperitoneal inoculation of Finkel Biskis Jenkins virus.<sup><xref ref-type="bibr" rid="bibr105-0300985811398252">105</xref></sup> Osteosarcomas with and without metastases in CzechII/EiJ and C3H/BiDa mice, respectively, were induced by neonatal intraperitoneal inoculation of the RA strain of murine polyomavirus.<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup> Osteosarcomas in cranial bones are a relatively frequent observation in many SV40 Large T antigen transgenic mice regardless of the promoter, suggesting a direct effect (J.P.S., unpublished observation).</p>
<p>Osteosarcomas induced by intraperitoneal administration of bone-seeking radionuclides <sup>224</sup>Ra, <sup>223</sup>Ra, and <sup>227</sup>Th were reported in C3H/HeEl.102, (BALB/c x CBA) F2, (C3Hx101) F1, and NMRI mice<sup><xref ref-type="bibr" rid="bibr64-0300985811398252">64</xref></sup> and by external irradiation with <sup>90</sup>Sr-<sup>90</sup>Y beta rays in ICR mice.<sup><xref ref-type="bibr" rid="bibr71-0300985811398252">71</xref></sup> In other studies, administration of radiostrontium (<sup>90</sup>Sr) was reported to cause osteosarcomas and skeletal hemangiosarcomas in CBA and C3H mice.
</p>
<p>Strains of mice varied widely with respect to metastases of osteosarcomas, and metastases were infrequent or nonexistent in some. Metastases of spontaneous osteosarcomas were noted in BALB/c,<sup><xref ref-type="bibr" rid="bibr27-0300985811398252">27</xref></sup> C3Hf/Sed;CB17-<italic>Prkdc<sup>scid</sup></italic>/<italic>Prkdc<sup>scid</sup></italic>,<sup><xref ref-type="bibr" rid="bibr39-0300985811398252">39</xref></sup> C57BL/6J,<sup><xref ref-type="bibr" rid="bibr14-0300985811398252">14</xref></sup> C57BL/10J,<sup><xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup> C57BL/Icrf,<sup><xref ref-type="bibr" rid="bibr26-0300985811398252">26</xref></sup> CF-1,<sup><xref ref-type="bibr" rid="bibr10-0300985811398252">10</xref></sup> NZB/Bl,<sup><xref ref-type="bibr" rid="bibr29-0300985811398252">29</xref></sup> and RF/Un<sub>(MTB)</sub> mice. Metastases were quite infrequent in NOD/ShiLtJ and NOD-derived mice<sup><xref ref-type="bibr" rid="bibr50-0300985811398252">50</xref></sup> and absent in AKR<sup><xref ref-type="bibr" rid="bibr1-0300985811398252">1</xref></sup> and B6C3F1<sup><xref ref-type="bibr" rid="bibr9-0300985811398252">9</xref></sup> mice. Among virally induced osteosarcomas, metastases were prominent in BALB/c and CD-1 mice inoculated with Moloney murine sarcoma virus<sup><xref ref-type="bibr" rid="bibr73-0300985811398252">73</xref></sup> and CzechII/EiJ and CZC3F1 mice inoculated with Murine polyoma virus.<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup> Metastases were not evident in CBA/J mice inoculated with the Finkel Biskis Jenkins virus.<sup><xref ref-type="bibr" rid="bibr77-0300985811398252">77</xref></sup></p>
<p>At The Jackson Laboratory osteosarcomas were diagnosed in mice of strains 129Sv/J, A/J, AKR/J (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 9, 10</xref>), B6;129P2-<italic>Nos2<sup>tm1Lau</sup></italic>/J, B6129SF2/J, B6C3F1/J, BALB/cJ, BALB/cByJ, BKS.Cg-<italic>Dock7<sup>m</sup>Lepr<sup>db</sup></italic>/++/J, C3D2F1/J, C3H/HeJ, C3.Smn.CB17-<italic>Prkdc<sup>scid</sup></italic>/J, C57BL/6J, CAF1/J, CBA/J, CBXNO-7, CWDAKRF1/J, CXJ-8/SlkJ, NOD/ShiLtJ (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 11, 12</xref>) and NOD derived (<xref ref-type="fig" rid="fig1-0300985811398252">Fig. 8</xref>), NOR/LtJ, and WBB6F1/J-<italic>Kit<sup>W</sup>/Kit<sup>W-v</sup></italic>/J. The age at necropsy varied from 49 days (NOD.CB17-<italic>Prkdc<sup>scid</sup></italic>/J female) to 537 days (NOD.Cg-<italic>Prkdc<sup>scid</sup>I12rg<sup>tm1Wjl</sup></italic>/SzJ female). Osteosarcomas were also found in mice transgenic for the Simian virus 40 tumor antigen (SV40 Tag)<sup><xref ref-type="bibr" rid="bibr40-0300985811398252">40</xref>,<xref ref-type="bibr" rid="bibr51-0300985811398252">51</xref>,<xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref>,<xref ref-type="bibr" rid="bibr106-0300985811398252">106</xref></sup> and in mice bearing targeted mutations of <italic>Trp53</italic> (<italic>Trp53<sup>tm1TyJ</sup></italic>),<sup>44</sup> in agreement with previous reports in the literature.</p>
</sec>
</sec>
<sec id="section14-0300985811398252">
<title>Vascular Tumors</title>
<sec id="section15-0300985811398252">
<title>Hemangioma</title>
<p>Hemangiomas are benign vascular tumors composed of blood-filled, endothelium-lined spaces. They are typically soft tissue tumors but can rarely arise as primary bone tumors, occurring more frequently in the axial skeleton than elsewhere in humans.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Histologically, hemangiomas consist of a partially circumscribed network of vascular spaces, usually lined by a single layer of well-differentiated endothelial cells embedded in a fibrous stroma. Intraosseous hemangiomas are extremely infrequent in laboratory mice<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref></sup> as well as dogs and cats.<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref></sup> They were reported in BALB/c mice (0.95% frequency).<sup><xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref></sup> An intraosseous hemangioma was observed in an HRS/J +/+ mouse at The Jackson Laboratory.</p>
</sec>
<sec id="section17-0300985811398252">
<title>Hemangiosarcoma</title>
<p>Hemangiosarcomas (hemangioendothelial sarcomas) are malignant vascular tumors composed of endothelium-lined vascular channels supported by various proportions of stroma.<sup><xref ref-type="bibr" rid="bibr30-0300985811398252">30</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> They are typically soft tissue tumors but can occasionally arise as primary bone tumors.<sup><xref ref-type="bibr" rid="bibr30-0300985811398252">30</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Histologically, hemangiosarcomas consist of malignant endothelial cells that differ in their degree of differentiation and cytologic atypia and form vascular channels and solid sheets embedded in a fibrovascular stroma (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 13, 14</xref>).<sup><xref ref-type="bibr" rid="bibr30-0300985811398252">30</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Intraosseous hemangiosarcomas are extremely infrequent in laboratory mice and domestic animals.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref>,<xref ref-type="bibr" rid="bibr56-0300985811398252">56</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup> The primary differential diagnosis for an intraosseous hemangiosarcoma is a telangiectatic osteosarcoma in which osteoblasts rather than neoplastic endothelial cells line the blood-filled spaces.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> A spontaneous intraosseous hemangiosarcoma (angiosarcoma) was reported in an NZB mouse.<sup><xref ref-type="bibr" rid="bibr41-0300985811398252">41</xref></sup> Hemangiosarcomas of bone were found in mice at The Jackson Laboratory of strains CD-1, DBA/2J, HRS/J, FVB/NJ-<italic>Trp53<sup>tm1TyJ</sup></italic>/J, B6;129-<italic>Oxt<sup>tm1Wsy</sup></italic>/J, B6.CAST-<italic>Gpi-1<sup>a</sup></italic>/EiJ, and NOD.Cg-<italic>Prkdc<sup>scid</sup>I12rg<sup>tm1Wjl</sup></italic>/SzJ (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 13</xref>, 14).</p>
</sec>
</sec>
<sec id="section18-0300985811398252">
<title>Miscellaneous Tumors and Lesions</title>
<sec id="section19-0300985811398252">
<title>Ossifying fibroma, osteofibroma, and osteofibrous dysplasia</title>
<p>Ossifying fibromas are rare fibro-osseous tumors that usually involve the mandible and maxilla in most species. They are typically solitary, slow growing, expansile, and sharply demarcated, and they distort the normal contour of the affected bone. They are morphologically similar to a fibroma but contain metaplastic bone. Histologically, ossifying fibromas are well demarcated from surrounding tissue by bone, and they consist of spindle-shape fibroblasts. The fibroblasts appear to transform into osteoblasts forming irregular spicules of woven bone. In general, ossifying fibromas are of relatively low cellularity with a higher proportion of fibrous stroma than bone. Lamellar bone is extremely rare in an ossifying fibroma but may be formed where woven bone trabeculae are resorbed and replaced.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr58-0300985811398252">58</xref>,<xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref>,<xref ref-type="bibr" rid="bibr95-0300985811398252">95</xref></sup></p>
<p>A few authors consider ossifying fibromas as being synonymous with osteofibroma or fibrous osteoma,<sup><xref ref-type="bibr" rid="bibr89-0300985811398252">89</xref></sup> while others describe them as being synonymous with cementifying fibroma when teeth are involved.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr58-0300985811398252">58</xref></sup> The latter authors describe osteofibromas as being distinct from ossifying fibromas and more similar to osteoblastomas. Such osteofibromas are typified as benign, expansile, noninvasive bone-forming tumors with a predilection for the vertebral column. Histologically, osteofibromas are characterized by mature trabecular bone within a densely cellular spindle cell stroma.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref>,<xref ref-type="bibr" rid="bibr59-0300985811398252">59</xref></sup> Human tumors previously described as ossifying fibroma are currently designated as osteofibrous dysplasia.<sup><xref ref-type="bibr" rid="bibr25-0300985811398252">25</xref>,<xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup> Osteofibrous dysplasia is characterized by a hypocellular spindle cell proliferation with the production of immature woven bone.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref></sup> Spontaneous ossifying fibromas (incidence not available) were reported in CD-1, CF-1, and NMRI mice.<sup><xref ref-type="bibr" rid="bibr2-0300985811398252">2</xref>,<xref ref-type="bibr" rid="bibr57-0300985811398252">57</xref></sup> A single case was diagnosed in a NONcNZO10/LtJ mouse (<xref ref-type="fig" rid="fig1-0300985811398252">Figs. 15, 16</xref>) at The Jackson Laboratory. The latter lesion had some microscopic features resembling those described in osteofibrous dysplasia of humans.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr96-0300985811398252">96</xref></sup></p>
</sec>
</sec>
<sec id="section21-0300985811398252">
<title>Experimental and Genetically Engineered Mouse Models</title>
<p>Numerous genetically engineered mouse models have contributed to the elucidation of genetic mechanisms involved in skeletal tumors.<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> Selected models and their characteristics are summarized below.</p>
<sec id="section22-0300985811398252">
<title>Exostoses (multiple) 1 and 2 (Ext1, Ext2)</title>
<p>The genes exostoses (multiple) 1 (<italic>EXT1</italic>) and exostoses (multiple) 2 (<italic>EXT2</italic>) encode proteins that function in the biosynthesis of heparan sulfate on the cell surface and in the extracellular matrix.<sup><xref ref-type="bibr" rid="bibr46-0300985811398252">46</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr91-0300985811398252">91</xref></sup> Germline loss-of-function mutations in <italic>EXT1</italic> and <italic>EXT2</italic> were associated with cartilaginous tumors and multiple hereditary exostoses in humans.<sup><xref ref-type="bibr" rid="bibr42-0300985811398252">42</xref>,<xref ref-type="bibr" rid="bibr46-0300985811398252">46</xref>,<xref ref-type="bibr" rid="bibr86-0300985811398252">86</xref>,<xref ref-type="bibr" rid="bibr91-0300985811398252">91</xref></sup> Mice with conditional inactivation of <italic>Ext1</italic> (<italic>Ext1<sup>e2ne</sup>°<sup>fl</sup></italic> and <italic>Ext1<sup>e2fl</sup></italic>) in chondrocytes were shown to develop osteochondromas by 6 to 10 weeks of age.<sup><xref ref-type="bibr" rid="bibr46-0300985811398252">46</xref></sup> Mice with a targeted mutation of <italic>Ext2</italic> (<italic>Ext2<sup>tm1Werb</sup></italic>) were shown to develop foci of chondrocyte hypertrophy by 2 weeks of age that progress to osteochondromas.<sup><xref ref-type="bibr" rid="bibr91-0300985811398252">91</xref></sup> Both are regarded as models of human multiple hereditary exostoses and are among the few currently available genetically engineered mouse models of benign bone tumors.</p>
</sec>
<sec id="section24-0300985811398252">
<title>GLI-Kruppel family member oncogene (Gli2)</title>
<p>Enchondromas were shown to develop with high frequency in mice with transgenic overexpression of the GLI-Kruppel family member oncogene (<italic>Gli2</italic>) in chondrocytes and with expression of a mutant form of the human parathyroid hormone/parathyroid hormone–related protein receptor (<italic>R150CPTHR1</italic>) in growth plates, both regulated by the Collagen 2a1 (<italic>Co12a1</italic>) promoter.<sup><xref ref-type="bibr" rid="bibr37-0300985811398252">37</xref></sup> Chondrosarcomas were found to develop on account of transgenic overexpression of the <italic>Gli2</italic> gene in chondrocytes under regulation of the <italic>Co12a1</italic> promoter in heterozygous <italic>Trp53<sup>tm1TyJ</sup></italic> mice.<sup><xref ref-type="bibr" rid="bibr35-0300985811398252">35</xref></sup> In the enchondroma model, chondrocyte proliferation mediated by Indian hedgehog (<italic>Ihh</italic>) signaling is thought to be the mechanism of tumorigenesis.<sup><xref ref-type="bibr" rid="bibr37-0300985811398252">37</xref></sup> In the chondrosarcoma model, overexpression of <italic>Gli2</italic> and deficiency of <italic>Trp53</italic> additively downregulate insulin-like growth factor binding protein 3 (<italic>Igfbp3</italic>), which in turn inhibits chondrocyte apoptosis to facilitate proliferation and transformation.<sup><xref ref-type="bibr" rid="bibr35-0300985811398252">35</xref></sup></p>
</sec>
<sec id="section25-0300985811398252">
<title>Nuclear factor of activated T cells, cytoplasmic calcineurin dependent-2 gene (Nfatc2)</title>
<p>Mice with targeted mutations in the <italic>Nfatc2</italic> gene (<italic>Nfatc2<sup>tm1Glm</sup></italic>) were shown to develop cartilaginous proliferations resembling chondrosarcoma. In these mice, chondrosarcomas developed predominantly in the shoulder, knee, hip, and ankle joints. In this model (by an unclear mechanism), <italic>Nfatc2</italic> functions as a repressor of chondrocyte differentiation and proliferation, and its loss facilitates excessive proliferation of chondrocytes.<sup><xref ref-type="bibr" rid="bibr84-0300985811398252">84</xref></sup></p>
</sec>
<sec id="section26-0300985811398252">
<title>Osteosarcoma-associated genes</title>
<p>The molecular mechanisms and genetic pathways implicated in osteosarcomagenesis include aberrations involving transformation-related protein 53 (<italic>Trp53</italic>),<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref>,<xref ref-type="bibr" rid="bibr15-0300985811398252">15</xref>,<xref ref-type="bibr" rid="bibr18-0300985811398252">18</xref>,<xref ref-type="bibr" rid="bibr19-0300985811398252">19</xref></sup> retinoblastoma 1 (<italic>Rb1</italic>),<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref>,<xref ref-type="bibr" rid="bibr15-0300985811398252">15</xref>,<xref ref-type="bibr" rid="bibr43-0300985811398252">43</xref>,<xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref>,<xref ref-type="bibr" rid="bibr101-0300985811398252">101</xref>,<xref ref-type="bibr" rid="bibr107-0300985811398252">107</xref></sup> myelocytomatosis oncogene (<italic>Myc</italic>),<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> Finkel Biskis Jenkins osteosarcoma oncogene (<italic>Fos</italic>),<sup><xref ref-type="bibr" rid="bibr16-0300985811398252">16</xref>,<xref ref-type="bibr" rid="bibr31-0300985811398252">31</xref>,<xref ref-type="bibr" rid="bibr87-0300985811398252">87</xref>,<xref ref-type="bibr" rid="bibr103-0300985811398252">103</xref></sup> hypermethylated in cancer 1 (<italic>Hic1</italic>),<sup><xref ref-type="bibr" rid="bibr11-0300985811398252">11</xref>,<xref ref-type="bibr" rid="bibr12-0300985811398252">12</xref></sup> GLI-Kruppel family member (<italic>Gli1</italic>),<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> fibroblast growth factor receptor 2 (<italic>Fgfr2</italic>),<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> runt-related transcription factor 2 (<italic>Runx</italic>),<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> osterix or the Sp7 transcription factor 7 (<italic>Osx</italic> or <italic>Sp7</italic>),<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> neurofibromatosis 2 (<italic>Nf2</italic>),<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup> and bone morphogenetic proteins and their receptors.<sup><xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref></sup> Genetically engineered mouse models that have contributed to understanding these mechanisms include mice with targeted mutations or conditional inactivation of BCL-2-associated x protein (<italic>Bax<sup>tm1SjK</sup></italic>) and cyclin-dependent kinase inhibitor 2A (<italic>Cdkn2a<sup>tm1Cjs</sup></italic>),<sup><xref ref-type="bibr" rid="bibr20-0300985811398252">20</xref></sup><italic>Hic1</italic> (<italic>Hic1<sup>tm1Sbb</sup></italic>),<sup><xref ref-type="bibr" rid="bibr11-0300985811398252">11</xref>,<xref ref-type="bibr" rid="bibr12-0300985811398252">12</xref></sup><italic>Nf2</italic> (<italic>Nf2<sup>tm1TyJ</sup></italic>),<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup><italic>Trp53</italic> (<italic>Trp53<sup>tm1Brd</sup></italic>/<italic>Trp53<sup>tm1TyJ</sup></italic>/<italic>Trp53<sup>tm1Brn</sup></italic>),<sup><xref ref-type="bibr" rid="bibr18-0300985811398252">18</xref>,<xref ref-type="bibr" rid="bibr19-0300985811398252">19</xref>,<xref ref-type="bibr" rid="bibr33-0300985811398252">33</xref>,<xref ref-type="bibr" rid="bibr44-0300985811398252">44</xref>,<xref ref-type="bibr" rid="bibr48-0300985811398252">48</xref>,<xref ref-type="bibr" rid="bibr54-0300985811398252">54</xref></sup><italic>Trp53</italic> (<italic>Trp53<sup>tm1TyJ</sup></italic>) and <italic>Nf2</italic> (<italic>Nf2<sup>tm1TyJ</sup></italic>),<sup><xref ref-type="bibr" rid="bibr67-0300985811398252">67</xref></sup><italic>Trp53</italic> (<italic>Trp53<sup>tm1TyJ</sup></italic>) and <italic>Rb1</italic> (<italic>Rb1<sup>tm1TyJ</sup></italic>),<sup><xref ref-type="bibr" rid="bibr107-0300985811398252">107</xref></sup><italic>Trp53</italic> (<italic>Trp53<sup>tm1TyJ</sup></italic>), and cyclin-dependent kinase inhibitor 2C (<italic>Cdkn2c<sup>tm1Yxi</sup></italic>)<sup><xref ref-type="bibr" rid="bibr15-0300985811398252">15</xref></sup> and mice with transgenic expression of <italic>c-fos</italic> (under the human metallothionein promoter or H2-K<sup>b</sup> class I MHC promoter)<sup><xref ref-type="bibr" rid="bibr31-0300985811398252">31</xref>,<xref ref-type="bibr" rid="bibr49-0300985811398252">49</xref>,<xref ref-type="bibr" rid="bibr87-0300985811398252">87</xref>,<xref ref-type="bibr" rid="bibr103-0300985811398252">103</xref></sup> or the SV40 Tag.<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref>,<xref ref-type="bibr" rid="bibr40-0300985811398252">40</xref>,<xref ref-type="bibr" rid="bibr51-0300985811398252">51</xref>,<xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref>,<xref ref-type="bibr" rid="bibr106-0300985811398252">106</xref></sup></p>
<p>Mice with mutations of <italic>Trp53</italic> in tandem with mutations of <italic>Rb1</italic> specifically in osteoblast precursors are among the most successful models of osteosarcoma.<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref>,<xref ref-type="bibr" rid="bibr101-0300985811398252">101</xref></sup> In one study, mice with conditional alleles of <italic>Trp53</italic> (<italic>Trp53<sup>tm1Brn</sup></italic>) and <italic>Rb1</italic> (<italic>Rb1<sup>tm3TyJ</sup></italic>) developed tumors that ranged in histology from fibroblastic with little osteoid or mineral to osteoblastic with abundant osteoid and mineral. Such tumors occurred most commonly in the lower jaw and upper jaw, followed by the hip and ribs and less frequently in the dorsal cranium, forelimb, and sternum.<sup><xref ref-type="bibr" rid="bibr101-0300985811398252">101</xref></sup> In another study employing concurrent loss of <italic>Trp53<sup>tm1TyJ</sup></italic> and <italic>Rb1<sup>tm1TyJ</sup></italic>, tumors arose in the femur, nasal bones, vertebral column, and skull.<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref></sup> Between both studies, the average age of tumor occurrence varied from 125 days in <italic>Trp53</italic> and <italic>Rb1</italic> double-null mice to 338 days in mice heterozygous for <italic>Trp53</italic> (<italic>Trp53</italic>+/–, <italic>Rb1</italic>+/+). Transformation of an Osterix (<italic>Osx1</italic>) expressing preosteoblast cell due to concurrent loss of <italic>Trp53</italic> and <italic>Rb1</italic> is implicated in the pathogenesis of osteosarcoma in these models.<sup><xref ref-type="bibr" rid="bibr6-0300985811398252">6</xref>,<xref ref-type="bibr" rid="bibr101-0300985811398252">101</xref></sup></p>
<p>Mice that bear the tumor antigen gene from SV40 Tag in their genome were also shown to develop osteosarcomas<sup><xref ref-type="bibr" rid="bibr5-0300985811398252">5</xref>,<xref ref-type="bibr" rid="bibr40-0300985811398252">40</xref>,<xref ref-type="bibr" rid="bibr51-0300985811398252">51</xref>,<xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref>,<xref ref-type="bibr" rid="bibr106-0300985811398252">106</xref></sup> and lesions resembling synovial chondromatosis.<sup><xref ref-type="bibr" rid="bibr98-0300985811398252">98</xref></sup> The lesions of chondromatosis reportedly involved the articular cartilages of the legs and feet in these mice.<sup><xref ref-type="bibr" rid="bibr98-0300985811398252">98</xref></sup> In SV40 Tag–induced osteosarcomas, sequestration and inactivation of the P53 and RB1 proteins by the SV40 Tag (usually, large T antigen) resulted in tumorigenesis in a promoter-independent manner. Tumors arose predominantly in the axial skeleton with variable involvement of the skull, vertebral column, sternum, ribs, shoulder, and pelvic girdle, with less frequent involvement of the humerus and femur.<sup><xref ref-type="bibr" rid="bibr5-0300985811398252">5</xref>,<xref ref-type="bibr" rid="bibr40-0300985811398252">40</xref>,<xref ref-type="bibr" rid="bibr51-0300985811398252">51</xref>,<xref ref-type="bibr" rid="bibr65-0300985811398252">65</xref>,<xref ref-type="bibr" rid="bibr106-0300985811398252">106</xref></sup></p>
<p>Human synovial sarcomas are marked by a signature translocation-mediated fusion of the Synovial Sarcoma Translocation, chromosome 18 (<italic>SYT</italic>) gene on chromosome 18q11 to the Sarcoma, Synovial, X breakpoint (<italic>SSX1</italic>, <italic>SSX2</italic>, or <italic>SSX4</italic>) gene on chromosome Xp11.<sup><xref ref-type="bibr" rid="bibr32-0300985811398252">32</xref></sup> The recently reported transgenic mouse model of synovial sarcoma based on conditional expression of the human <italic>SYT-SSX</italic> fusion gene is a unique genetically engineered model of synovial sarcoma,<sup><xref ref-type="bibr" rid="bibr32-0300985811398252">32</xref></sup> an extremely rare spontaneous tumor in laboratory mice.<sup><xref ref-type="bibr" rid="bibr22-0300985811398252">22</xref>,<xref ref-type="bibr" rid="bibr55-0300985811398252">55</xref></sup> In these mice, tumors were induced by conditional expression of the human <italic>SYT-SSX</italic> fusion gene in myoblast precursors expressing the myogenic regulatory factor <italic>Myf5.</italic>
<sup><xref ref-type="bibr" rid="bibr32-0300985811398252">32</xref></sup> Tumors occurred between 3 to 5 months of age in the skeletal muscle in intercostal areas and near joints of the limbs. These tumors recapitulated the histologic, immunohistochemical, and transcriptional profiles of human synovial sarcoma. This study implicates <italic>Myf5</italic>-specific myoblast lineage cells in the histogenesis of synovial sarcoma.<sup><xref ref-type="bibr" rid="bibr32-0300985811398252">32</xref></sup> Reports also exist of synovial sarcomas induced by interscapular injections of cannabinoids in BALB/c and C57BL/6 mice. In this model, cannabinoids are thought to initiate tumorigenesis, and sex steroids are thought to facilitate progression. A clear mechanistic correlate is yet to be elucidated.<sup><xref ref-type="bibr" rid="bibr93-0300985811398252">93</xref></sup></p>
</sec>
</sec>
<sec id="section27-0300985811398252">
<title>Gene Network Analysis</title>
<p>A list of candidate genes was created from genes with a confirmed involvement in the pathogenesis of neoplasms of bone and additional genes known to significantly influence the former. Hypothetical fold change scores were assigned to each listed gene, and gene network analysis was performed to deduce network interactions between genes.</p>
<p>Results of the analysis (Supplementary <xref ref-type="table" rid="table4-0300985811398252">Table 4</xref> and Supplementary Figs. 1–4, available at <ext-link ext-link-type="uri" xlink:href="http://vet.sagepub.com/supplemental">http://vet.sagepub.com/supplemental</ext-link>) suggested that transformation related protein 53 (<italic>Trp53</italic>), retinoblastoma 1 (<italic>Rb1</italic>), neurofibromatosis 2 (<italic>Nf2</italic>), Werner syndrome homolog, human (<italic>Wrn</italic>), nuclear factor of activated T cells, cytoplasmic calcineurin dependent-2 (<italic>Nfatc2</italic>), and hypermethylated in cancer 1 (<italic>Hic1</italic>) could be most significant among those genes whose loss or inhibition led to the development of bone neoplasms in mouse models. Results of the analysis also suggested that bone morphogenic protein receptor type 2 (<italic>Bmpr2</italic>), cadherin 11 (<italic>Cdh11</italic>), collagen type 2 alpha 1 subunit (<italic>C012a1</italic>), catenin beta 1 (<italic>Ctnnb1</italic>), fibroblast growth factor receptor 2 (<italic>Fgfr2</italic>), Finkel Biskis Jenkins osteosarcoma oncogene (<italic>Fos</italic>), GLI-Kruppel family member GLI1 (<italic>Gli1</italic>), and GLI-Kruppel family member GLI2 (<italic>Gli2</italic>) could be most significant among those genes whose overexpression or activation led to the development of bone neoplasms in mouse models. In addition to the aforementioned genes, the analysis suggested that constitutive photomorphogenic homolog subunit 3, Arabidopsis thaliana (<italic>Cops3</italic>), endothelin 1 (<italic>Edn1</italic>), twist homolog 1, Drosophila (<italic>Twist1</italic>), sequestosome 1 (<italic>Sqstm1</italic>), RecQ protein-like 4 (<italic>Recq14</italic>), and insulin-like growth factor binding protein (<italic>Igfbp3</italic>) could be most significant among the network of genes involved in the pathogenesis of bone neoplasms.</p>
<table-wrap id="table4-0300985811398252" position="float">
<label>Table 4.</label>
<caption>
<p>Benign and Malignant Bone Tumors in Strains of Mice From The Jackson Laboratory Diagnostic Necropsy Archives<sup><xref ref-type="table-fn" rid="table-fn8-0300985811398252">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table4-0300985811398252" xlink:href="10.1177_0300985811398252-table4.tif"/>
<graphic alternate-form-of="table4-0300985811398252" xlink:href="10.1177_0300985811398252-table4a.tif"/>
<graphic alternate-form-of="table4-0300985811398252" xlink:href="10.1177_0300985811398252-table4b.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="2">Chondroma</th>
<th colspan="2">Osteochondroma</th>
<th colspan="2">Chondrosarcoma</th>
<th colspan="2">Osteoma</th>
<th colspan="2">Ossifying fibroma</th>
<th colspan="2">Osteosarcoma</th>
<th colspan="2">Hemangioma</th>
<th colspan="2">Hemangiosarcoma</th>
</tr>
<tr>
<th>Strain</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
<th>F</th>
<th>A</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<italic>OUTBRED STOCK</italic>
</td>
</tr>
<tr>
<td>CD-1</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>1.81 (1/55)</td>
<td>230</td>
</tr>
<tr>
<td colspan="1">
<italic>INBRED STRAINS</italic>
</td>
</tr>
<tr>
<td>129S1/SvImJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>129X1/SvJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.91 (1/109)</td>
<td>188</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>A/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.13 (1/752)</td>
<td>168</td>
<td>
</td>
<td>
</td>
<td>0.13 (1/752)</td>
<td>111</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>AKR/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.77 (4/513)</td>
<td>137.75</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>BALB/cByJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.1 (1/991)</td>
<td>166</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>BALB/cJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.1 (2/1,892)</td>
<td>225.5</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C3H/HeJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.13 (1/1,344)</td>
<td>200</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.04 (1/2,326)</td>
<td>325</td>
<td>0.04 (1/2,326)</td>
<td>47</td>
<td>
</td>
<td>
</td>
<td>0.09 (2/2,326)</td>
<td>251.5</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6NJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/10J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>CBA/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.15 (1/669)</td>
<td>191</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>DBA/1J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>DBA/2J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.19 (1/538)</td>
<td>247</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.19 (1/538)</td>
<td>57</td>
</tr>
<tr>
<td>FVB/NJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>NOD/ShiLtJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>11.5 (43/375)</td>
<td>133</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>NOR/LtJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>6.66 (1/15)</td>
<td>235</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>SJL/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>TALLYHO/JngJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>HYBRID STRAINS</italic>
</td>
</tr>
<tr>
<td>B6129SF2/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>25 (1/4)</td>
<td>263</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>B6C3F1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.74 (1/134)</td>
<td>338</td>
<td>
</td>
<td>
</td>
<td>0.74 (1/135)</td>
<td>348</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>B6CBAF1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>B6D2F1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
<italic>HYBRID STRAINS</italic>
</td>
</tr>
<tr>
<td>B6SJLF1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C3D2F1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>4.5 (1/22)</td>
<td>199</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>CAF1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.44 (1/224)</td>
<td>298</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>CB6F1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>CWDAKRF1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>100 (2/2)</td>
<td>281.5</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>NZBWF1/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>RECOMBINANT INBRED STRAINS</italic>
</td>
</tr>
<tr>
<td>CXJ-8/SalkJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>100 (1/1)</td>
<td>148</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>CBXNO-7</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>100 (2/2)</td>
<td>194.5</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>RECOMBINANT CONGENIC STRAINS</italic>
</td>
</tr>
<tr>
<td>NONcNZO10/LtJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>25 (1/4)</td>
<td>186</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>SPONTANEOUS MUTANT STRAINS</italic>
</td>
</tr>
<tr>
<td>BKS.Cg-<italic>Dock7<sup>m</sup></italic> +/+ <italic>Lepr<sup>db</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.52 (1/189)</td>
<td>191</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>HRS/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.22 (1/441)</td>
<td>175</td>
<td>0.22 (1/441)</td>
<td>175</td>
</tr>
<tr>
<td>WBB6F1/J-<italic>Kit<sup>W</sup>/Kit<sup>W-v</sup>/J</italic>
</td>
<td>
</td>
<td>
</td>
<td>16.7 (1/6)</td>
<td>44</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>16.7 (1/6)</td>
<td>295</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>SPONTANEOUS AND TARGETED SCID MUTANT STRAINS</italic>
</td>
</tr>
<tr>
<td>C3SnSmn.CB17-<italic>Prkdc<sup>scid</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>0.64 (1/157)</td>
<td>177</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>NOD.CB17-<italic>Prkdc<sup>scid</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>5.7 (11/194)</td>
<td>150.8</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>NOD.Cg-<italic>Prkdc<sup>scid</sup>Il2rg<sup>tm1Wjl</sup></italic>/SzJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>3.2 (5/157)</td>
<td>188</td>
<td>
</td>
<td>
</td>
<td>0.6 (1/157)</td>
<td>268</td>
</tr>
<tr>
<td colspan="1">
<italic>CONGENIC MUTANT STRAINS</italic>
</td>
</tr>
<tr>
<td>B6.CAST-<italic>Gpi-1<sup>a</sup></italic>/EiJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>25 (1/4)</td>
<td>236</td>
</tr>
<tr>
<td>C3.SW-<italic>H2<sup>b</sup></italic>/SnJ</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>9.09 (1/11)</td>
<td>103</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>GEM STRAINS: Trp53 MUTANTS</italic>
</td>
</tr>
<tr>
<td>129-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>4.34 (1/23)</td>
<td>51</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
<italic>GEM STRAINS: Trp53 MUTANTS</italic>
</td>
</tr>
<tr>
<td>B6.129S2-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>2.53 (6/237)</td>
<td>105</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>BALB/cJ-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>5.9 (1/17)</td>
<td>70</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C.129S2(B6)-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>6.67 (1/15)</td>
<td>70</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C3H/HeOuJ-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>11.11 (1/9)</td>
<td>358</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6J-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>2.5 (1/40)</td>
<td>87</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>FVB/NJ-<italic>Trp53<sup>tm1TyJ</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>14.28 (1/7)</td>
<td>87</td>
</tr>
<tr>
<td colspan="1">
<italic>GEM STRAINS: SV40 Tag TRANSGENIC</italic>
</td>
</tr>
<tr>
<td>B6.129S6-<italic>CD4<sup>tm1Knw</sup></italic>/J;B6-Tg(Amy1TAg)501Knw/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>50 (2/4)</td>
<td>285.5</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6J-Tg(Amy1TAg)335Knw/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>100 (1/1)</td>
<td>358</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6J-Tg(Amy1TAg)501Knw/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>100 (1/1)</td>
<td>342</td>
<td>
</td>
<td>
</td>
<td>100 (1/1)</td>
<td>463</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6J-Tg(SV)419Bri/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>33.33 (1/3)</td>
<td>308</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>C57BL/6J-Tg(WAPTAg)3Knw/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>92.3 (12/13)</td>
<td>169</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td colspan="1">
<italic>GEM STRAINS: OTHER</italic>
</td>
</tr>
<tr>
<td>B6;129-<italic>Oxt<sup>tm1Wsy</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>100 (1/1)</td>
<td>498</td>
</tr>
<tr>
<td>B6;129P2-<italic>Nos2<sup>tm1Lau</sup></italic>/J</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>8.3 (1/12)</td>
<td>174</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>NOD.129P2(B6)-<italic>B2m<sup>tm1Unc</sup></italic>/J</td>
<td>16.7 (1/6)</td>
<td>37</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0300985811398252">
<p>
<sup>a</sup> F, frequency of tumors in percentages (number of cases by number of necropsies); A, average age of observation of tumor (average age at necropsy) in days. Tumor frequencies and average ages for males and females are available in Supplementary <xref ref-type="table" rid="table1-0300985811398252">Tables 1</xref> and <xref ref-type="table" rid="table2-0300985811398252">2</xref> (available at <ext-link ext-link-type="uri" xlink:href="http://vet.sagepub.com/supplemental">http://vet.sagepub.com/supplemental</ext-link>). No bone tumors were found in the diagnostic archives for the inbred and hybrid strains highlighted in gray. The frequencies were considered nonrepresentative for strains with less than 100 total necropsies (highlighted in gray). Columns highlighted in darker gray indicate that there were no documented cases of that tumor type for that strain in the necropsy archives.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section28-0300985811398252">
<title>Discussion</title>
<p>Spontaneous bone tumors were infrequent in most strains of mice with the exceptions of osteosarcomas in NZBR/BI, NOD, and NOD-derived mice and osteomas in CF-1 and OF-1 mice. The most popular inbred strains of mice currently available through The Jackson Laboratory are 129S1/SvImJ, 129X1/SvJ, A/J, AKR/J, BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, C57BL/6NJ, C57BL/10J, CBA/J, DBA/1J, DBA/2J, FVB/NJ, NOD/ShiLtJ, and SJL/J (JAX Mice, <ext-link ext-link-type="uri" xlink:href="http://www.jaxmice.org/">http://www.jaxmice.org/</ext-link>, September 2010). Among these, 129S1/SvImJ, C57BL/10J, DBA/1J, FVB/NJ, and SJL/J mice had no documented bone neoplasms in the diagnostic necropsy archives. This is noteworthy even though the colony sizes of these strains have varied through the years, many of the submitted mice were 8 months or younger, and focus of the diagnostic necropsy program was evaluation of sick mice rather than a systematic study of cancer with equal numbers of age- and sex-matched mice. Systematic aging studies<sup><xref ref-type="bibr" rid="bibr109-0300985811398252">109</xref></sup> have been designed to better address such questions. In those mice with documented neoplasms, spontaneous osteogenic neoplasms occurred more frequently than cartilaginous, vascular, and hematopoietic ones, with osteoma being the most common benign bone tumor and with osteosarcoma being the most common malignancy of bone. Spontaneous cartilaginous neoplasms were the least frequent tumors of bone in mice, in direct contrast to chondrogenic neoplasms, the second-most common bone tumor type, after hematolymphoid malignancies in humans. In this context it is worth noting that chondrogenic tumors were produced by targeted mutations of <italic>Nfatc2</italic> in mice,<sup><xref ref-type="bibr" rid="bibr84-0300985811398252">84</xref></sup> but no correlative mutations of <italic>NFAT1</italic> were identified in a set of human chondrosarcomas and enchondromas.<sup><xref ref-type="bibr" rid="bibr3-0300985811398252">3</xref></sup> This disparity needs further investigation.</p>
<p>Another noteworthy aspect is that strains of mice with spontaneous neoplasms of bone varied in their propensity to develop metastases. Metastases were infrequent or nonexistent in many studies. At The Jackson Laboratory, the age at necropsy for mice with spontaneous or genetically engineered malignant neoplasms of bone ranged from 41 to 537 days (<italic>M</italic> = 215.55) and 35 to 990 days (<italic>M</italic> = 393.17) in the literature, and metastases were relatively rare. Most metastases that occurred were of osteosarcomas, and lung was the favored site. In some of these cases with relatively younger ages of occurrence, mice not living long enough to develop metastases could be a contributory factor. A more important determinant of strain-specific differences in metastasis is their inherent diversity with respect to genes that influence cell–cell and cell–matrix adhesion and cell migration. In a recently published study, the difference between C3H/BiDa and CzechII/Ei mice in metastasis of Murine polyoma virus–induced osteosarcomas was attributed to variability in the levels of the metalloproteinase MMP-2 and the transcription factor NFAT.<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup> CZC3F1 mice in this study exhibited metastases, suggesting dominance of the metastatic phenotype.<sup><xref ref-type="bibr" rid="bibr97-0300985811398252">97</xref></sup> In studies on spontaneous osteosarcomas, metastases were evident in “black” strains of mice, such as C57BL/Icrf,<sup><xref ref-type="bibr" rid="bibr26-0300985811398252">26</xref></sup> C57BL/6J,<sup><xref ref-type="bibr" rid="bibr14-0300985811398252">14</xref></sup> and C57BL/10J,<sup><xref ref-type="bibr" rid="bibr100-0300985811398252">100</xref></sup> and absent in B6C3F1 mice.<sup><xref ref-type="bibr" rid="bibr9-0300985811398252">9</xref></sup> Such an apparent contrast between 2 F1 hybrid strains of mice involving the C3H strain warrants further investigation of bone tumor metastases in inbred and hybrid strains.</p>
<p>Conspicuous disparities exist between classification systems for human, veterinary, and mouse bone and joint tumors. Unified systems of classification and characterization for human, veterinary, mouse, and genetically engineered bone tumors that reconcile differences in designation for similar entities would enhance comparative studies of tumors of the skeleton across species. The Mouse Pathology Ontology (Pathbase; <ext-link ext-link-type="uri" xlink:href="http://eulep.pdn.cam.ac.uk/Pathology_Ontology/index.php">http://eulep.pdn.cam.ac.uk/Pathology_Ontology/index.php</ext-link>) developed by a consortium of veterinary and physician pathologists has reconciled these differences.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We gratefully acknowledge D. Boggess for retrieval of archived necropsy records and materials; J. Miller, E. Taylor, and M. McKluskey for retrieval of archived glass slides; the Department of Histopathology and Microscopy Sciences for preparation of histologic sections from archived paraffin blocks; J. Hammer for assistance with preparation of figure panels; T. Stearns for assistance with the Ingenuity IPA Pathway Analysis Software and preparation of gene networks; N. Buckley for assistance with formatting some references; Dr. C. Bult for advice on interpretation of the gene network analyses; and Drs E. Leiter, L. Shultz, and W. Beamer for critical comments and suggestions.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0300985811398252">
<p>The authors declared that they received no commercial financial support for research or authorship of this article.</p>
</fn>
<fn fn-type="other" id="fn2-0300985811398252">
<p>This work was supported in part by grants from the National Institutes of Health (CA34196, JPS), the Ellison Medical Foundation (JPS), and institutional shared services at The Jackson Laboratory (AK, OF).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0300985811398252">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albala</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Esparza</surname>
<given-names>AR</given-names>
</name>
</person-group>: <article-title>Transplantable osteogenic sarcoma in inbred AKR mice</article-title>. <source>Cancer Res</source> <volume>29</volume>:
<fpage>1519</fpage>–<lpage>1522</lpage>, <year>1969</year>.
</citation>
</ref>
<ref id="bibr2-0300985811398252">
<label>2</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Albassam</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Courtney</surname>
<given-names>CL:</given-names>
</name>
</person-group>
<article-title>Non-neoplastic and neoplastic lesions of the bone</article-title>. <italic>In</italic>: <source>Pathobiology of the Aging Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Dungworth</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Capen</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Carlton</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>JM</given-names>
</name>
</person-group> <volume>vol. 2</volume>, pp. <fpage>425</fpage>–<lpage>437</lpage>. <publisher-name>ILSI Press</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>, <year>1996</year>.
</citation>
</ref>
<ref id="bibr3-0300985811398252">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoyama</surname>
<given-names>TNS</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>T</given-names>
</name>
</person-group>: <article-title>Mutation analyses of the <italic>NFAT1</italic> gene in chondrosarcomas and enchondromas</article-title>. <source>Cancer Lett</source> <volume>186</volume>:
<fpage>59</fpage>–<lpage>67</lpage>, <year>2002</year>.
</citation>
</ref>
<ref id="bibr4-0300985811398252">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ash</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Loutit</surname>
<given-names>JF</given-names>
</name>
</person-group>: <article-title>The ultrastructure of skeletal hemangiosarcomas induced in mice by Strontium-90</article-title>. <source>J Pathol</source> <volume>122</volume>:
<fpage>209</fpage>–<lpage>218</lpage>, <year>1977</year>.
</citation>
</ref>
<ref id="bibr5-0300985811398252">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behringer</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Peschon</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Messing</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>Heart and bone tumors in transgenic mice</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>85</volume>:
<fpage>2648</fpage>–<lpage>2652</lpage>, <year>1998</year>.
</citation>
</ref>
<ref id="bibr6-0300985811398252">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Calo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Landman</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Danielian</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>West</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Fonhoue</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bouxsein</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>JA</given-names>
</name>
</person-group>: <article-title>Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>105</volume>:
<fpage>11851</fpage>–<lpage>11856</lpage>, <year>2008</year>.
</citation>
</ref>
<ref id="bibr7-0300985811398252">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bomhard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
</person-group>: <article-title>Spontaneous tumors in NMRI mice from carcinogenicity studies</article-title>. <source>Exp Pathol</source> <volume>36</volume>:
<fpage>129</fpage>–<lpage>145</lpage>, <year>1989</year>.
</citation>
</ref>
<ref id="bibr8-0300985811398252">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrasco</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Sukhdeo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Protopopova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Enos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carrasco</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pinkus</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Munshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Horner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Protopopov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Tonon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>DePinho</surname>
<given-names>RA</given-names>
</name>
</person-group>: <article-title>The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis</article-title>. <source>Cancer Cell</source> <volume>11</volume>:
<fpage>349</fpage>–<lpage>360</lpage>, <year>2007</year>.
</citation>
</ref>
<ref id="bibr9-0300985811398252">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frith</surname>
<given-names>CH</given-names>
</name>
</person-group>: <article-title>Spontaneous neoplasms in B6C3F1 mice</article-title>. <source>Toxicol Lett</source> <volume>60</volume>:
<fpage>91</fpage>–<lpage>98</lpage>, <year>1992</year>.
</citation>
</ref>
<ref id="bibr10-0300985811398252">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charles</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Turusov</surname>
<given-names>VS</given-names>
</name>
</person-group>: <article-title>Bone Tumors in CF-1 mice</article-title>. <source>Lab Anim</source> <volume>8</volume>:
<fpage>137</fpage>–<lpage>144</lpage>, <year>1974</year>.
</citation>
</ref>
<ref id="bibr11-0300985811398252">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Zahnow</surname>
<given-names>CA</given-names>
</name>
</person-group>: <article-title>Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis</article-title>. <source>Cancer Cell</source> <volume>6</volume>:<fpage>387</fpage>, <year>2004</year>.
</citation>
</ref>
<ref id="bibr12-0300985811398252">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>MG</given-names>
</name>
</person-group>: <article-title>Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors</article-title>. <source>Nat Genet</source> <volume>33</volume>:<fpage>197</fpage>, <year>2003</year>.
</citation>
</ref>
<ref id="bibr13-0300985811398252">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chesi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Sebag</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chng</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Affer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tiedemann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Valdez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cattoretti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bergsagel</surname>
<given-names>PL</given-names>
</name>
</person-group>: <article-title>AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies</article-title>. <source>Cancer Cell</source> <volume>13</volume>:
<fpage>167</fpage>–<lpage>180</lpage>, <year>2008</year>.
</citation>
</ref>
<ref id="bibr14-0300985811398252">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cockman-Thomas</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Innskeep</surname>
<given-names>W 2nd</given-names>
</name>
<name>
<surname>Mondy</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Swearengen</surname>
<given-names>JR</given-names>
</name>
</person-group>: <article-title>Spontaneous osteosarcoma in a C57BL/6J mouse</article-title>. <source>Lab Anim Sci</source> <volume>44</volume>:
<fpage>531</fpage>–<lpage>533</lpage>, <year>1994</year>.
</citation>
</ref>
<ref id="bibr15-0300985811398252">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damo</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>DS</given-names>
</name>
</person-group>: <article-title>Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways</article-title>. <source>Mol Carcinog</source> <volume>42</volume>:
<fpage>109</fpage>–<lpage>120</lpage>, <year>2005</year>.
</citation>
</ref>
<ref id="bibr16-0300985811398252">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mehic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bakiri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schilling</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Mandic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Priemel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Idarraga</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Reschke</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Amling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>EF</given-names>
</name>
</person-group>: <article-title>Essential role of RSK2 in c-Fos-dependent osteosarcoma development</article-title>. <source>J Clin Invest</source> <volume>115</volume>:
<fpage>664</fpage>–<lpage>672</lpage>, <year>2005</year>.
</citation>
</ref>
<ref id="bibr17-0300985811398252">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawe</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Freund</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ballmer-Hofer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Talmage</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>TL</given-names>
</name>
</person-group>: <article-title>Variations in polyoma virus genotype in relation to tumor induction in mice: characterization of wild type strains with widely differing tumor profiles</article-title>. <source>Am J Pathol</source> <volume>127</volume>:
<fpage>243</fpage>–<lpage>261</lpage>, <year>1987</year>.
</citation>
</ref>
<ref id="bibr18-0300985811398252">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donehower</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Slagle</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>CA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Butel</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title>. <source>Nature</source> <volume>356</volume>:
<fpage>215</fpage>–<lpage>221</lpage>, <year>1992</year>.
</citation>
</ref>
<ref id="bibr19-0300985811398252">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donehower</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>CA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>Effects of genetic background on tumorigenesis in p53-deficient mice</article-title>. <source>Mol Carcinog</source> <volume>14</volume>:
<fpage>16</fpage>–<lpage>22</lpage>, <year>1995</year>.
</citation>
</ref>
<ref id="bibr20-0300985811398252">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eischen</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rehg</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Korsmeyer</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>JL</given-names>
</name>
</person-group>: <article-title>Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice</article-title>. <source>Cancer Res</source> <volume>62</volume>:
<fpage>2184</fpage>–<lpage>2191</lpage>, <year>2002</year>.
</citation>
</ref>
<ref id="bibr21-0300985811398252">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eppig</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bult</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Kadin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ringwald</surname>
<given-names>M</given-names>
</name>
</person-group>; <article-title>MGI staff: Mouse genome informatics (MGI) resources for pathology and toxicology</article-title>. <source>Toxicol Pathol</source> <volume>35</volume>: <fpage>456</fpage>–<lpage>457</lpage>, <year>2007</year>.</citation>
</ref>
<ref id="bibr22-0300985811398252">
<label>22</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Ernst</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Wadsworth</surname>
<given-names>PF:</given-names>
</name>
</person-group>
<article-title>Skeletal system and teeth</article-title>. <italic>In</italic>:
<source>International Classification of Rodent Tumors: The Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
</person-group> pp. <fpage>389</fpage>–<lpage>415</lpage>. <publisher-name>Springer Verlag</publisher-name>, <publisher-loc>Berlin, Germany</publisher-loc>, <year>2001</year>.</citation>
</ref>
<ref id="bibr23-0300985811398252">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finkel</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Biskis</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Jinkins</surname>
<given-names>PB</given-names>
</name>
</person-group>: <article-title>Virus induction of osteosarcomas in mice</article-title>. <source>Science</source> <volume>151</volume>:
<fpage>698</fpage>–<lpage>701</lpage>, <year>1966</year>.
</citation>
</ref>
<ref id="bibr24-0300985811398252">
<label>24</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname>
<given-names>CDM:</given-names>
</name>
</person-group>
<article-title>Soft tissue tumors</article-title>. <italic>In</italic>:
<source>Diagnostic Histopathology of Tumors</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Fletcher</surname>
<given-names>CDM</given-names>
</name>
</person-group>
<volume>vol. 1</volume>, <edition>3rd ed</edition>., pp. <fpage>1568</fpage>–<lpage>1572</lpage>. <publisher-name>Churchill Livingstone Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>, <year>2007</year>.
</citation>
</ref>
<ref id="bibr25-0300985811398252">
<label>25</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname>
<given-names>CDM</given-names>
</name>
<name>
<surname>Unni</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>F:</given-names>
</name>
</person-group>
<article-title>WHO classification of bone tumours</article-title>. <italic>In</italic>:
<source>Pathology and Genetics of Tumours of Soft Tissue and Bone</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Fletcher</surname>
<given-names>CDM</given-names>
</name>
<name>
<surname>Unni</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>F</given-names>
</name>
</person-group> pp. <fpage>225</fpage>–<lpage>226</lpage>. <publisher-name>International Agency for Research on Cancer</publisher-name>, <publisher-loc>Lyons, France</publisher-loc>, <year>2002</year>.</citation>
</ref>
<ref id="bibr26-0300985811398252">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franks</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Rowlatt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chesterman</surname>
<given-names>FC</given-names>
</name>
</person-group>: <article-title>Naturally occurring bone tumors in C57BL-Lcrf mice</article-title>. <source>J Natl Cancer Inst</source> <volume>50</volume>:
<fpage>431</fpage>–<lpage>438</lpage>, <year>1973</year>.
</citation>
</ref>
<ref id="bibr27-0300985811398252">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frith</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Highman</surname>
<given-names>B</given-names>
</name>
</person-group>: <article-title>Osteosarcomas in BALB/c female mice</article-title>. <source>Lab Anim Sci</source> <volume>32</volume>:
<fpage>60</fpage>–<lpage>63</lpage>, <year>1982</year>.
</citation>
</ref>
<ref id="bibr28-0300985811398252">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>LB</given-names>
</name>
</person-group>: <article-title>The application of immunohistochemistry in the diagnosis of bone tumors and tumor-like lesions</article-title>. <source>Skeletal Radiol</source> <volume>34</volume>:
<fpage>755</fpage>–<lpage>770</lpage>, <year>2005</year>.
</citation>
</ref>
<ref id="bibr29-0300985811398252">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geary</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Bielschowsky</surname>
<given-names>M</given-names>
</name>
</person-group>: <article-title>Osteosarcomas in NZBR/BI mice</article-title>. <source>Pathology</source> <volume>11</volume>:
<fpage>197</fpage>–<lpage>206</lpage>, <year>1979</year>.
</citation>
</ref>
<ref id="bibr30-0300985811398252">
<label>30</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Greaves</surname>
<given-names>P:</given-names>
</name>
</person-group>
<article-title>Soft tissue tumors including cardiovascular lesions</article-title>. <italic>In</italic>:
<source>Pathology of Neoplasia and Preneoplasia in Rodents</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Bannasch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gossner</surname>
<given-names>W</given-names>
</name>
</person-group>
<volume>vol. 2</volume>, pp. <fpage>183</fpage>–<lpage>202</lpage>. <publisher-name>Schattauer</publisher-name>, <publisher-loc>Stuttgart, Germany</publisher-loc>, <year>1997</year>.</citation>
</ref>
<ref id="bibr31-0300985811398252">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigoriadis</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Schellander</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>ZQ</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>EF</given-names>
</name>
</person-group>: <article-title>Osteoblasts are target cells for transformation in c-fos transgenic mice</article-title>. <source>J Cell Biol</source> <volume>122</volume>:
<fpage>685</fpage>–<lpage>701</lpage>, <year>1993</year>.
</citation>
</ref>
<ref id="bibr32-0300985811398252">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haldar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Coffin</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lessnick</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Capecchi</surname>
<given-names>MR</given-names>
</name>
</person-group>: <article-title>A conditional mouse model of synovial sarcoma: insights into a myogenic origin</article-title>. <source>Cancer Cell</source> <volume>11</volume>:
<fpage>375</fpage>–<lpage>388</lpage>, <year>2007</year>.
</citation>
</ref>
<ref id="bibr33-0300985811398252">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>CA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Bradley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Donehower</surname>
<given-names>LA</given-names>
</name>
</person-group>: <article-title>Genetic background alters the spectrum of tumors that develop in p53-deficient mice</article-title>. <source>FASEB J</source> <volume>7</volume>:
<fpage>938</fpage>–<lpage>943</lpage>, <year>1993</year>.
</citation>
</ref>
<ref id="bibr34-0300985811398252">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Highman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Greenman</surname>
<given-names>DL</given-names>
</name>
</person-group>: <article-title>Osseous changes and osteosacomas in mice continuously fed diets containing diethylstilbestrol or 17 beta-estradiol</article-title>. <source>J Natl Cancer Inst</source> <volume>67</volume>:
<fpage>653</fpage>–<lpage>662</lpage>, <year>1981</year>.
</citation>
</ref>
<ref id="bibr35-0300985811398252">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stojanovski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Whetstone</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>QX</given-names>
</name>
<name>
<surname>Mau</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wunder</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Alman</surname>
<given-names>B</given-names>
</name>
</person-group>: <article-title>Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors</article-title>. <source>Cancer Cell</source> <volume>16</volume>:
<fpage>126</fpage>–<lpage>136</lpage>, <year>2009</year>.
</citation>
</ref>
<ref id="bibr36-0300985811398252">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gialamas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jelinek</surname>
<given-names>F</given-names>
</name>
</person-group>: <article-title>Multiple osteomas in mice</article-title>. <source>Vet Pathol</source> <volume>31</volume>:
<fpage>429</fpage>–<lpage>434</lpage>, <year>1994</year>.
</citation>
</ref>
<ref id="bibr37-0300985811398252">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopyan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gokgoz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gensure</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Jüppner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Andrulis</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Wunder</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Alman</surname>
<given-names>BA</given-names>
</name>
</person-group>: <article-title>A mutant PTH/PTHrP type I receptor in enchondromatosis</article-title>. <source>Nat Genet</source> <volume>30</volume>:
<fpage>306</fpage>–<lpage>310</lpage>, <year>2002</year>.
</citation>
</ref>
<ref id="bibr38-0300985811398252">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopyan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nadesan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wunder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alman</surname>
<given-names>BA</given-names>
</name>
</person-group>: <article-title>Dysregulation of hedgehog signalling predisposes to synovial chondromatosis</article-title>. <source>J Pathol</source> <volume>206</volume>:
<fpage>143</fpage>–<lpage>150</lpage>, <year>2005</year>.
</citation>
</ref>
<ref id="bibr39-0300985811398252">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Suit</surname>
<given-names>HD</given-names>
</name>
</person-group>: <article-title>Spontaneous osteosarcoma in a severe combined immunodeficient (SCID/Sed) mouse</article-title>. <source>Contemp Top Lab Anim Sci</source> <volume>35</volume>:
<fpage>75</fpage>–<lpage>77</lpage>, <year>1996</year>.
</citation>
</ref>
<ref id="bibr40-0300985811398252">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Husler</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kotopoulis</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Tennent</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Kunig</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>BB</given-names>
</name>
</person-group>: <article-title>Lactation-induced WAP-SV40 Tag transgene expression in C57BL/6J mice leads to mammary carcinoma</article-title>. <source>Transgenic Res</source> <volume>7</volume>:
<fpage>253</fpage>–<lpage>263</lpage>, <year>1998</year>.
</citation>
</ref>
<ref id="bibr41-0300985811398252">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inada</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yumoto</surname>
<given-names>T</given-names>
</name>
</person-group>: <article-title>Naturally occurring angiosarcoma of the tibia in an NZB mouse</article-title>. <source>Acta Pathol Jpn</source> <volume>28</volume>:
<fpage>99</fpage>–<lpage>109</lpage>, <year>1978</year>.
</citation>
</ref>
<ref id="bibr42-0300985811398252">
<label>42</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Inwards</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Unni</surname>
<given-names>KK:</given-names>
</name>
</person-group>
<article-title>Bone tumors</article-title>. <italic>In</italic>:
<source>Sternberg’s Diagnostic Surgical Pathology</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Mills</surname>
<given-names>SE</given-names>
</name>
</person-group>
<volume>vol 1</volume>., pp. <fpage>236</fpage>–<lpage>284</lpage>. <publisher-name>Lippincott Williams and Wilkins</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>, <year>2010</year>.</citation>
</ref>
<ref id="bibr43-0300985811398252">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fazeli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Goodell</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>: <article-title>Effects of an Rb mutation in the mouse</article-title>. <source>Nature</source> <volume>359</volume>:
<fpage>295</fpage>–<lpage>300</lpage>, <year>1992</year>.
</citation>
</ref>
<ref id="bibr44-0300985811398252">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Halachmi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>: <article-title>Tumor spectrum analysis in p53-mutant mice</article-title>. <source>Curr Biol</source> <volume>4</volume>:
<fpage>1</fpage>–<lpage>7</lpage>, <year>1994</year>.
</citation>
</ref>
<ref id="bibr45-0300985811398252">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joliat</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Umeda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Lynes</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Shultz</surname>
<given-names>LD</given-names>
</name>
</person-group>: <article-title>Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma</article-title>. <source>In Vivo</source> <volume>16</volume>:
<fpage>223</fpage>–<lpage>228</lpage>, <year>2002</year>.
</citation>
</ref>
<ref id="bibr46-0300985811398252">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Piombo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Searby</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kurriger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grabellus</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Roughley</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Morcuende</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Buckwalter</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Capecchi</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Vortkamp</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sheffield</surname>
<given-names>VC</given-names>
</name>
</person-group>: <article-title>A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>107</volume>:
<fpage>2054</fpage>–<lpage>2059</lpage>, <year>2010</year>.
</citation>
</ref>
<ref id="bibr47-0300985811398252">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jonkers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berns</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>Conditional mouse models of sporadic cancer</article-title>. <source>Nat Rev Cancer</source> <volume>2</volume>:
<fpage>251</fpage>–<lpage>265</lpage>, <year>2002</year>.
</citation>
</ref>
<ref id="bibr48-0300985811398252">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jonkers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meuwissen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van</surname>
<given-names>der Gulden H</given-names>
</name>
<name>
<surname>Peterse</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van</surname>
<given-names>der Valk M</given-names>
</name>
<name>
<surname>Berns</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer</article-title>. <source>Nat Genet</source> <volume>29</volume>:
<fpage>418</fpage>–<lpage>425</lpage>, <year>2001</year>.
</citation>
</ref>
<ref id="bibr49-0300985811398252">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kansara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DM</given-names>
</name>
</person-group>: <article-title>Molecular pathogenesis of osteosarcoma</article-title>. <source>DNA Cell Biol</source> <volume>26</volume>:
<fpage>1</fpage>–<lpage>18</lpage>, <year>2007</year>.
</citation>
</ref>
<ref id="bibr50-0300985811398252">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavirayani</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>O</given-names>
</name>
</person-group>: <article-title>Retrospective study of spontaneous osteosarcomas in the nonobese diabetic strain and nonobese diabetic-derived substrains of mice</article-title>. <source>Vet Pathol</source> <volume>47</volume>:
<fpage>482</fpage>–<lpage>487</lpage>, <year>2010</year>.
</citation>
</ref>
<ref id="bibr51-0300985811398252">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knowles</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>McCarrick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Solter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Damjanov</surname>
<given-names>I</given-names>
</name>
</person-group>: <article-title>Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene</article-title>. <source>Am J Pathol</source> <volume>137</volume>:
<fpage>259</fpage>–<lpage>262</lpage>, <year>1990</year>.
</citation>
</ref>
<ref id="bibr52-0300985811398252">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krupke</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Begley</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bult</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Eppig</surname>
<given-names>JT</given-names>
</name>
</person-group>: <article-title>The Mouse Tumor Biology database</article-title>. <source>Nat Rev Cancer</source> <volume>8</volume>:
<fpage>459</fpage>–<lpage>465</lpage>, <year>2008</year>.
</citation>
</ref>
<ref id="bibr53-0300985811398252">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deavers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parant</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>G</given-names>
</name>
</person-group>: <article-title>EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model</article-title>. <source>Cancer Res</source> <volume>68</volume>:
<fpage>8968</fpage>–<lpage>8975</lpage>, <year>2008</year>.
</citation>
</ref>
<ref id="bibr54-0300985811398252">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McDonnell</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Montes</surname>
<given-names>de Oca Luna R</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mims</surname>
<given-names>B</given-names>
</name>
<name>
<surname>El-Naggar</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>G</given-names>
</name>
</person-group>: <article-title>High metastatic potential in mice inheriting a targeted p53 missense mutation</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>97</volume>:
<fpage>4174</fpage>–<lpage>4179</lpage>, <year>2000</year>.
</citation>
</ref>
<ref id="bibr55-0300985811398252">
<label>55</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Lombard</surname>
<given-names>LS:</given-names>
</name>
</person-group>
<article-title>Neoplasms of musculoskeletal system</article-title>. <italic>In</italic>:
<source>The Mouse in Biomedical Research</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Foster</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>JG</given-names>
</name>
</person-group>
<volume>vol. 4</volume>, pp. <fpage>501</fpage>–<lpage>511</lpage>. <publisher-name>Academic Press</publisher-name>, <publisher-loc>New York, NY</publisher-loc>, <year>1982</year>.</citation>
</ref>
<ref id="bibr56-0300985811398252">
<label>56</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Leininger</surname>
<given-names>JR:</given-names>
</name>
</person-group>
<article-title>Bones, joints and synovia</article-title>. <italic>In</italic>:
<source>Pathology of the Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Maronpot</surname>
<given-names>RR</given-names>
</name>
</person-group> pp. <fpage>665</fpage>–<lpage>671</lpage>. <publisher-name>Cache River</publisher-name>, <publisher-loc>Vienna, IL</publisher-loc>, <year>1999</year>.</citation>
</ref>
<ref id="bibr57-0300985811398252">
<label>57</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Luz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gossner</surname>
<given-names>W:</given-names>
</name>
</person-group>
<article-title>Neoplastic bone lesions in the mouse</article-title>. <italic>In</italic>:
<source>Pathology of Neoplasia and Preneoplasia in Rodents</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Bannasch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gossner</surname>
<given-names>W</given-names>
</name>
</person-group>
<volume>vol. 1</volume>, pp. <fpage>142</fpage>–<lpage>150</lpage>. <publisher-name>Schattauer</publisher-name>, <publisher-loc>Stuttgart, Germany</publisher-loc>, <year>1994</year>.</citation>
</ref>
<ref id="bibr58-0300985811398252">
<label>58</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Luz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gossner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>AB:</given-names>
</name>
</person-group>
<article-title>Ossifying fibroma, mouse</article-title>. <italic>In</italic>:
<source>Monographs on Pathology of Laboratory Animals: Cardiovascular and Musculoskeletal Systems</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Jones</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>RD</given-names>
</name>
</person-group> pp. <fpage>228</fpage>–<lpage>233</lpage>. <publisher-name>Springer Verlag</publisher-name>, <publisher-loc>Berlin, Germany</publisher-loc>, <year>1991</year>.</citation>
</ref>
<ref id="bibr59-0300985811398252">
<label>59</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Luz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gossner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>AB:</given-names>
</name>
</person-group>
<article-title>Osteofibroma: mouse</article-title>. <italic>In</italic>:
<source>Monographs on Pathology of Laboratory Animals: Cardiovascular and Musculoskeletal Systems</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Jones</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>RD</given-names>
</name>
</person-group> pp. <fpage>224</fpage>–<lpage>227</lpage>. <publisher-name>Springer Verlag</publisher-name>, <publisher-loc>Berlin, Germany</publisher-loc>, <year>1991</year>.</citation>
</ref>
<ref id="bibr60-0300985811398252">
<label>60</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Luz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gossner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>AB:</given-names>
</name>
</person-group>
<article-title>Osteosarcoma, spontaneous and radiation induced, mouse</article-title>. <italic>In</italic>:
<source>Monographs on Pathology of Laboratory Animals: Cardiovascular and Musculoskeletal Systems</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Jones</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>RD</given-names>
</name>
</person-group> pp. <fpage>202</fpage>–<lpage>213</lpage>. <publisher-name>Springer Verlag</publisher-name>, <publisher-loc>Berlin, Germany</publisher-loc>, <year>1991</year>.</citation>
</ref>
<ref id="bibr61-0300985811398252">
<label>61</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Luz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>J:</given-names>
</name>
</person-group>
<article-title>Osteoma, spontaneous and virus-induced, mouse</article-title>. <italic>In</italic>:
<source>Monographs on Pathology of Laboratory Animals: Cardiovascular and Musculoskeletal Systems</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Jones</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>RD</given-names>
</name>
</person-group> pp. <fpage>182</fpage>–<lpage>189</lpage>. <publisher-name>Springer Verlag</publisher-name>, <publisher-loc>Berlin, Germany</publisher-loc>, <year>1991</year>.</citation>
</ref>
<ref id="bibr62-0300985811398252">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madison</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Rabstein</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>WR</given-names>
</name>
</person-group>: <article-title>Mortality rate and spontaneous lesions found in 2,928 untreated BALB/cCr mice</article-title>. <source>J Natl Cancer Inst</source> <volume>40</volume>:
<fpage>683</fpage>–<lpage>685</lpage>, <year>1968</year>.
</citation>
</ref>
<ref id="bibr63-0300985811398252">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mitsumori</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kitazawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Enomoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Inui</surname>
<given-names>K</given-names>
</name>
</person-group>: <article-title>Mortality, major cause of moribundity, and spontaneous tumors in CD-1 mice</article-title>. <source>Toxicol Pathol</source> <volume>16</volume>:
<fpage>340</fpage>–<lpage>349</lpage>, <year>1988</year>.
</citation>
</ref>
<ref id="bibr64-0300985811398252">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marquart</surname>
<given-names>KH:</given-names>
</name>
</person-group>
<article-title>Retroviral particles in radionuclide-induced murine osteosarcomas: mouse strain-related differences</article-title>. <source>Lab Anim Sci</source> <volume>39</volume>:
<fpage>127</fpage>–<lpage>131</lpage>, <year>1989</year>.
</citation>
</ref>
<ref id="bibr65-0300985811398252">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marton</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Damjanov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Currier</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>BB</given-names>
</name>
</person-group>: <article-title>Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas</article-title>. <source>Transgenic Res</source> <volume>9</volume>:
<fpage>115</fpage>–<lpage>125</lpage>, <year>2000</year>.
</citation>
</ref>
<ref id="bibr66-0300985811398252">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Boysen</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Currier</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>BB</given-names>
</name>
</person-group>: <article-title>Confounded carcinogenicity study of sodium fluoride in CD-1 mice</article-title>. <source>Regul Toxicol Pharmacol</source> <volume>18</volume>:
<fpage>154</fpage>–<lpage>168</lpage>, <year>1993</year>.
</citation>
</ref>
<ref id="bibr67-0300985811398252">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClatchey</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Saotome</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mercer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Crowley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gusella</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
</person-group>: <article-title>Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors</article-title>. <source>Genes Dev</source> <volume>12</volume>:
<fpage>1121</fpage>–<lpage>1133</lpage>, <year>1998</year>.
</citation>
</ref>
<ref id="bibr68-0300985811398252">
<label>68</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Mikaelian</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ichiki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>JM:</given-names>
</name>
</person-group>
<article-title>Diversity of spontaneous neoplasms in commonly used inbred strains and stocks of laboratory mice</article-title>. <italic>In</italic>:
<source>The Laboratory Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Hedrich</surname>
<given-names>H</given-names>
</name>
</person-group>, pp. <fpage>345</fpage>–<lpage>354</lpage>. <publisher-name>Elsevier</publisher-name>, <publisher-loc>London, UK</publisher-loc>, <year>2004</year>.</citation>
</ref>
<ref id="bibr69-0300985811398252">
<label>69</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>ED:</given-names>
</name>
</person-group>
<article-title>Characteristic tumors</article-title>. <italic>In</italic>:
<source>Biology of the Laboratory Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Green</surname>
<given-names>EL</given-names>
</name>
</person-group>
<edition>2nd ed</edition>., pp. <fpage>521</fpage>–<lpage>562</lpage>. <publisher-name>Dover Publications</publisher-name>, <publisher-loc>New York, NY</publisher-loc>, <year>1991</year>.</citation>
</ref>
<ref id="bibr70-0300985811398252">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakakuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shimokawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ojima</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>A spontaneous transplantable osteogenic sarcoma in AKR/Ms mice</article-title>. <source>Gann</source> <volume>67</volume>:
<fpage>513</fpage>–<lpage>521</lpage>, <year>1976</year>.
</citation>
</ref>
<ref id="bibr71-0300985811398252">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ootsuyama</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tanooka</surname>
<given-names>H</given-names>
</name>
</person-group>: <article-title>Induction of osteosarcomas in mouse lumbar vertebrae by repeated external beta-irradiation</article-title>. <source>Cancer Res</source> <volume>49</volume>:
<fpage>1562</fpage>–<lpage>1564</lpage>, <year>1989</year>.
</citation>
</ref>
<ref id="bibr72-0300985811398252">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Percy</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Jonas</surname>
<given-names>AM</given-names>
</name>
</person-group>: <article-title>Incidence of spontaneous tumors in CD (R) -1 HaM-ICR mice</article-title>. <source>J Natl Cancer Inst</source> <volume>46</volume>:
<fpage>1045</fpage>–<lpage>1065</lpage>, <year>1971</year>.
</citation>
</ref>
<ref id="bibr73-0300985811398252">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peretti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Torri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marinoni</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Facchini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Scaglione</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>G</given-names>
</name>
</person-group>: <article-title>Experimental osteosarcoma in the mouse, induced by Moloney’s murine sarcoma virus</article-title>. <source>Ital J Orthop Traumatol</source> <volume>6</volume>:
<fpage>255</fpage>–<lpage>268</lpage>, <year>1980</year>.
</citation>
</ref>
<ref id="bibr74-0300985811398252">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Rabstein</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Spahn</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Madison</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>RJ</given-names>
</name>
</person-group>: <article-title>Incidence of spontaneous neoplasms in breeding and retired breeder BALB-cCr mice throughout the natural life span</article-title>. <source>Int J Cancer</source> <volume>10</volume>:
<fpage>273</fpage>–<lpage>282</lpage>, <year>1972</year>.
</citation>
</ref>
<ref id="bibr75-0300985811398252">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picci</surname>
<given-names>P:</given-names>
</name>
</person-group>
<article-title>Osteosarcoma (osteogenic sarcoma)</article-title>. <source>Orphanet J Rare Dis</source> <volume>2</volume>:<fpage>6</fpage>, <year>2007</year>.</citation>
</ref>
<ref id="bibr76-0300985811398252">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prejean</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Peckham</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Casey</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Griswold</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Weisburger</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Weisburger</surname>
<given-names>JH</given-names>
</name>
</person-group>: <article-title>Spontaneous tumors in Sprague-Dawley rats and Swiss mice</article-title>. <source>Cancer Res</source> <volume>33</volume>:
<fpage>2768</fpage>–<lpage>2773</lpage>, <year>1973</year>.
</citation>
</ref>
<ref id="bibr77-0300985811398252">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>DB</given-names>
</name>
</person-group>: <article-title>FBJ virus-induced tumours in mice: a histopathological study of FBJ virus tumours and their relevance to murine and human osteosarcoma arising in bone</article-title>. <source>Br J Cancer</source> <volume>26</volume>:
<fpage>15</fpage>–<lpage>27</lpage>, <year>1972</year>.
</citation>
</ref>
<ref id="bibr78-0300985811398252">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pybus</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>EW</given-names>
</name>
</person-group>: <article-title>The gross pathology of spontaneous bone tumors in mice</article-title>. <source>Am J Cancer</source> <volume>40</volume>:
<fpage>47</fpage>–<lpage>53</lpage>, <year>1940</year>.
</citation>
</ref>
<ref id="bibr79-0300985811398252">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pybus</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>EW</given-names>
</name>
</person-group>: <article-title>The histology of spontaneous bone tumors in mice</article-title>. <source>Am J Cancer</source> <volume>40</volume>:
<fpage>54</fpage>–<lpage>61</lpage>, <year>1940</year>.
</citation>
</ref>
<ref id="bibr80-0300985811398252">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pybus</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>EW</given-names>
</name>
</person-group>: <article-title>Spontaneous bone tumors of mice</article-title>. <source>Am J Cancer</source> <volume>33</volume>:
<fpage>98</fpage>–<lpage>111</lpage>, <year>1938</year>.
</citation>
</ref>
<ref id="bibr81-0300985811398252">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabstein</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Spahn</surname>
<given-names>GJ</given-names>
</name>
</person-group>: <article-title>Spontaneous tumors and pathologic lesions in SWR-J mice</article-title>. <source>J Natl Cancer Inst</source> <volume>50</volume>:
<fpage>751</fpage>–<lpage>758</lpage>, <year>1973</year>.
</citation>
</ref>
<ref id="bibr82-0300985811398252">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Croese</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Zurcher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Van den Enden-Vieveen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>de</surname>
<given-names>Leeuw AM</given-names>
</name>
</person-group>: <article-title>Animal model of human disease: multiple myeloma</article-title>. <source>Am J Pathol</source> <volume>132</volume>:
<fpage>593</fpage>–<lpage>597</lpage>, <year>1988</year>.
</citation>
</ref>
<ref id="bibr83-0300985811398252">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Van</surname>
<given-names>Arkel C</given-names>
</name>
<name>
<surname>Hopstaken</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>HogenEsch</surname>
<given-names>H</given-names>
</name>
</person-group>: <article-title>Tenfold increased incidence of spontaneous multiple myeloma in long-term immunosuppressed aging C57BL/KaLwRij mice</article-title>. <source>Clin Immunol Immunopathol</source> <volume>79</volume>:
<fpage>155</fpage>–<lpage>162</lpage>, <year>1996</year>.
</citation>
</ref>
<ref id="bibr84-0300985811398252">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranger</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Gerstenfeld</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gravallese</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Glimcher</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Glimcher</surname>
<given-names>LH</given-names>
</name>
</person-group>: <article-title>The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis</article-title>. <source>J Exp Med</source> <volume>191</volume>:
<fpage>9</fpage>–<lpage>22</lpage>, <year>2000</year>.
</citation>
</ref>
<ref id="bibr85-0300985811398252">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rehm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Deerberg</surname>
<given-names>F</given-names>
</name>
</person-group>: <article-title>Influence of food restriction and body fat on life span and tumour incidence in female outbred Han:NMRI mice and two sublines</article-title>. <source>Z Versuchstierkd</source> <volume>27</volume>:
<fpage>240</fpage>–<lpage>283</lpage>, <year>1985</year>.
</citation>
</ref>
<ref id="bibr86-0300985811398252">
<label>86</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>A:</given-names>
</name>
</person-group>
<article-title>Bones, joints and soft-tissue tumors</article-title>. <italic>In</italic>:
<source>Robbins and Cotran Pathologic Basis of Disease</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Kumar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Abbas</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Fausto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Aster</surname>
<given-names>JC</given-names>
</name>
</person-group>
<edition>8th ed</edition>., pp. <fpage>1223</fpage>–<lpage>1235</lpage>. <publisher-name>Saunders Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>, <year>2010</year>.</citation>
</ref>
<ref id="bibr87-0300985811398252">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruther</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Komitowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>EF</given-names>
</name>
</person-group>: <article-title>c-fos expression induces bone tumors in transgenic mice</article-title>. <source>Oncogene</source> <volume>4</volume>:
<fpage>861</fpage>–<lpage>865</lpage>, <year>1989</year>.
</citation>
</ref>
<ref id="bibr88-0300985811398252">
<label>88</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Seymour</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ichiki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mikaelian</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Boggess</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP:</given-names>
</name>
</person-group>
<article-title>Necropsy methods</article-title>. <italic>In</italic>:
<source>The Laboratory Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Hedrich</surname>
<given-names>H</given-names>
</name>
</person-group>, pp. <fpage>495</fpage>–<lpage>516</lpage>. <publisher-name>Elsevier</publisher-name>, <publisher-loc>London, UK</publisher-loc>, <year>2004</year>.</citation>
</ref>
<ref id="bibr89-0300985811398252">
<label>89</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Slayter</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Boosinger</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Pool</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Dämmrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Misdorp</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>S:</given-names>
</name>
</person-group>
<article-title>Histological Classification of Bone and Joint Tumors of Domestic Animals</article-title>. <source>Armed Forces Institute of Pathology</source>, <publisher-loc>Washington, DC</publisher-loc>, <year>1994</year>.</citation>
</ref>
<ref id="bibr90-0300985811398252">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname>
<given-names>QG</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grosjean</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Saeuberli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lavanchy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Beermann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Acha-Orbea</surname>
<given-names>H</given-names>
</name>
</person-group>: <article-title>In vivo transformation of mouse conventional CD8alpha+ dendritic cells leads to progressive multisystem histiocytosis</article-title>. <source>Blood</source> <volume>111</volume>:
<fpage>2073</fpage>–<lpage>2082</lpage>, <year>2008</year>.
</citation>
</ref>
<ref id="bibr91-0300985811398252">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stickens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zak</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Rougier</surname>
<given-names>N</given-names>
</name>
</person-group>: <article-title>Mice deficient in Ext2 lack heparan sulfate and develop exostoses</article-title>. <source>Development</source> <volume>132</volume>:
<fpage>5055</fpage>–<lpage>5068</lpage>, <year>2006</year>.
</citation>
</ref>
<ref id="bibr92-0300985811398252">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swarm</surname>
<given-names>RL:</given-names>
</name>
</person-group>
<article-title>Transplantation of a murine chondrosarcoma in mice of different inbred strains</article-title>. <source>J Natl Cancer Inst</source> <volume>31</volume>:
<fpage>953</fpage>–<lpage>975</lpage>, <year>1963</year>.
</citation>
</ref>
<ref id="bibr93-0300985811398252">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szepsenwol</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Casales</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Murison</surname>
<given-names>GL</given-names>
</name>
</person-group>: <article-title>Experimentally produced synovial sarcoma in mice</article-title>. <source>Oncology</source> <volume>42</volume>:
<fpage>61</fpage>–<lpage>67</lpage>, <year>1985</year>.
</citation>
</ref>
<ref id="bibr94-0300985811398252">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kurata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fukushima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>N</given-names>
</name>
</person-group>: <article-title>Spontaneous tumors in aging (C57BL/6N x C3H/HeN)F1 (B6C3F1) mice</article-title>. <source>Toxicol Pathol</source> <volume>16</volume>:
<fpage>321</fpage>–<lpage>326</lpage>, <year>1988</year>.
</citation>
</ref>
<ref id="bibr95-0300985811398252">
<label>95</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>K:</given-names>
</name>
</person-group>
<article-title>Bone and joints</article-title>. <italic>In</italic>:
<source>Jubb Kennedy and Palmer’s Pathology of Domestic Animals</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Maxie</surname>
<given-names>MG</given-names>
</name>
</person-group>
<volume>vol. 1</volume>, <edition>5th ed</edition>., pp. <fpage>110</fpage>–<lpage>127</lpage>. <publisher-name>Saunders Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>, <year>2007</year>.</citation>
</ref>
<ref id="bibr96-0300985811398252">
<label>96</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Unni</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Inwards</surname>
<given-names>CY:</given-names>
</name>
</person-group>
<article-title>Tumors of the osteoarticular system</article-title>. <italic>In</italic>:
<source>Diagnostic Histopathology of Tumors</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Fletcher</surname>
<given-names>CDM</given-names>
</name>
</person-group>
<volume>vol. 2</volume>, pp. <fpage>1593</fpage>–<lpage>1651</lpage>. <publisher-name>Churchill Livingstone Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>, <year>2007</year>.</citation>
</ref>
<ref id="bibr97-0300985811398252">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velupillai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>T</given-names>
</name>
</person-group>: <article-title>Polyoma virus-induced osteosarcomas in inbred strains of mice: host determinants of metastasis</article-title>. <source>PLoS Pathog</source> <volume>6</volume>:<fpage>e1000733</fpage>, <year>2010</year>.
</citation>
</ref>
<ref id="bibr98-0300985811398252">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verschoyle</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nolan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Greaves</surname>
<given-names>P</given-names>
</name>
</person-group>: <article-title>Articular chondromatosis and chrondroid metaplasia in transgenic TAg mice</article-title>. <source>Toxicol Pathol</source> <volume>32</volume>:
<fpage>22</fpage>–<lpage>25</lpage>, <year>2004</year>.
</citation>
</ref>
<ref id="bibr99-0300985811398252">
<label>99</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wadsworth</surname>
<given-names>PF:</given-names>
</name>
</person-group>
<article-title>Classification of bone neoplasms and presentation of data on the incidences and types in C57BL/10J mice</article-title>. <italic>In</italic>:
<source>Pathobiology of the Aging Mouse</source>, ed. <person-group person-group-type="editor">
<name>
<surname>Mohr</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Dungworth</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Capen</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Carlton</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>JM</given-names>
</name>
</person-group>
<volume>vol. 2</volume>, pp. <fpage>439</fpage>–<lpage>443</lpage>. <publisher-name>ILSI Press</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>, <year>1996</year>.</citation>
</ref>
<ref id="bibr100-0300985811398252">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wadsworth</surname>
<given-names>PF</given-names>
</name>
</person-group>: <article-title>Tumours of the bone in C57BL/10J mice</article-title>. <source>Lab Anim</source> <volume>23</volume>:
<fpage>324</fpage>–<lpage>327</lpage>, <year>1998</year>.
</citation>
</ref>
<ref id="bibr101-0300985811398252">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walkley</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Qudsi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sankaran</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gostissa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Rodda</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Snay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dunning</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Alt</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Orkin</surname>
<given-names>SH</given-names>
</name>
</person-group>: <article-title>Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease</article-title>. <source>Genes Dev</source> <volume>22</volume>:
<fpage>1662</fpage>–<lpage>1676</lpage>, <year>2008</year>.
</citation>
</ref>
<ref id="bibr102-0300985811398252">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>LL</given-names>
</name>
</person-group>: <article-title>Biology of osteogenic sarcoma</article-title>. <source>Cancer J</source> <volume>11</volume>:
<fpage>294</fpage>–<lpage>305</lpage>, <year>2005</year>.
</citation>
</ref>
<ref id="bibr103-0300985811398252">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>ZQ</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schellander</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Grigoriadis</surname>
<given-names>AE</given-names>
</name>
</person-group>: <article-title>c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos</article-title>. <source>Cancer Res</source> <volume>55</volume>:
<fpage>6244</fpage>–<lpage>6251</lpage>, <year>1995</year>.
</citation>
</ref>
<ref id="bibr104-0300985811398252">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Squire</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Linhart</surname>
<given-names>MS</given-names>
</name>
</person-group>: <article-title>Neoplastic and nonneoplastic lesions in aging (C57BL/6N x C3H/HeN)F1 (B6C3F1) mice</article-title>. <source>J Natl Cancer Inst</source> <volume>63</volume>:
<fpage>849</fpage>–<lpage>854</lpage>, <year>1979</year>.
</citation>
</ref>
<ref id="bibr105-0300985811398252">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>DM</given-names>
</name>
</person-group>: <article-title>Histogenesis and morphology of periosteal sarcomas induced by FBJ virus in NIH Swiss mice</article-title>. <source>Cancer Res</source> <volume>36</volume>:
<fpage>3985</fpage>–<lpage>3992</lpage>, <year>1976</year>.
</citation>
</ref>
<ref id="bibr106-0300985811398252">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkie</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Baetscher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Messing</surname>
<given-names>A</given-names>
</name>
</person-group>: <article-title>Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen</article-title>. <source>Oncogene</source> <volume>9</volume>:
<fpage>2889</fpage>–<lpage>2895</lpage>, <year>1994</year>.
</citation>
</ref>
<ref id="bibr107-0300985811398252">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mukai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
</person-group>: <article-title>Cooperative tumorigenic effects of germline mutations in Rb and p53</article-title>. <source>Nat Genet</source> <volume>7</volume>:
<fpage>480</fpage>–<lpage>484</lpage>, <year>1994</year>.
</citation>
</ref>
<ref id="bibr108-0300985811398252">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Ryffel</surname>
<given-names>B</given-names>
</name>
</person-group>: <article-title>Osteomas in OF-1 mice: no alteration in biologic behavior during long-term treatment with cyclosporine</article-title>. <source>J Natl Cancer Inst</source> <volume>75</volume>:
<fpage>897</fpage>–<lpage>903</lpage>, <year>1985</year>.
</citation>
</ref>
<ref id="bibr109-0300985811398252">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tsaih</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Petkova</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>de Evsikova C</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marion</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bogue</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Bult</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Churchill</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Paigen</surname>
<given-names>B</given-names>
</name>
</person-group>: <article-title>Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels</article-title>. <source>Aging Cell</source> <volume>8</volume>:
<fpage>277</fpage>–<lpage>287</lpage>, <year>2009</year>.
</citation>
</ref>
</ref-list>
</back>
</article>